WO1999044994A1 - Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists - Google Patents

Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists Download PDF

Info

Publication number
WO1999044994A1
WO1999044994A1 PCT/US1999/003281 US9903281W WO9944994A1 WO 1999044994 A1 WO1999044994 A1 WO 1999044994A1 US 9903281 W US9903281 W US 9903281W WO 9944994 A1 WO9944994 A1 WO 9944994A1
Authority
WO
WIPO (PCT)
Prior art keywords
added
condition treated
product
reaction mixture
nmr
Prior art date
Application number
PCT/US1999/003281
Other languages
French (fr)
Inventor
Thomas E. Rogers
Peter G. Ruminski
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to OA1200000238A priority Critical patent/OA11530A/en
Priority to CA002322207A priority patent/CA2322207A1/en
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Priority to BR9908470-8A priority patent/BR9908470A/en
Priority to UA2000095148A priority patent/UA71906C2/en
Priority to JP2000534538A priority patent/JP2002505323A/en
Priority to APAP/P/2000/001893A priority patent/AP1244A/en
Priority to IL13765399A priority patent/IL137653A0/en
Priority to SK1300-2000A priority patent/SK13002000A3/en
Priority to HU0100865A priority patent/HUP0100865A3/en
Priority to KR1020007009774A priority patent/KR20010041584A/en
Priority to PL99342726A priority patent/PL342726A1/en
Priority to EP99937927A priority patent/EP1060164A1/en
Priority to AU32947/99A priority patent/AU753230B2/en
Priority to EA200000804A priority patent/EA200000804A1/en
Priority to EEP200000506A priority patent/EE200000506A/en
Publication of WO1999044994A1 publication Critical patent/WO1999044994A1/en
Priority to IS5582A priority patent/IS5582A/en
Priority to NO20004316A priority patent/NO315703B1/en
Priority to BG104740A priority patent/BG104740A/en
Priority to HR20000574A priority patent/HRP20000574A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Definitions

  • the present invention relates to pharmaceutical agents (compounds) which are useful as ⁇ v ⁇ 3 integrin antagonists and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by a v p3 by inhibiting or antagonizing ⁇ v ⁇ s integrins.
  • Integrins are a group of cell surface glycoproteins which mediate cell adhesion and therefore are useful mediators of cell adhesion interactions which occur during various biological processes. Integrins are heterodimers composed of noncovalently linked ⁇ and ⁇ polypeptide subunits. Currently eleven different ⁇ subunits have been identified and six different ⁇ subunits have been identified. The various ⁇ subunits can combine with various ⁇ subunits to form distinct integrins.
  • the integrin identified as ⁇ v ⁇ 3 (also known as the vitronectin receptor) has been identified as an integrin which plays a role in various conditions or disease states including tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, including macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration (e.g. restenosis). Additionally, it has been found that such agents would be useful as antivirals, antifungals and antimicrobials.
  • ⁇ v ⁇ 3 integrin and other ⁇ v containing integrins bind to a number of Arg-Gly-Asp (RGD) containing matrix macromolecules.
  • RGD Arg-Gly-Asp
  • Compounds containing the RGD sequence mimic extracellular matrix ligands so as to bind to cell surface receptors.
  • RGD peptides in general are non-selective for RGD dependent integrins. For example, most RGD peptides which bind to ⁇ v ⁇ s also bind to ⁇ v ⁇ 5, ⁇ v ⁇ and ⁇ b ⁇ 3 .
  • Antagonism of platelet ⁇ H b ⁇ 3 (also known as the fibrinogen receptor) is known to block platelet aggregation in humans.
  • fibrinogen receptor also known as the fibrinogen receptor
  • Tumor cell invasion occurs by a three step process: 1) tumor cell attachment to extracellular matrix; 2) proteoiytic dissolution of the matrix; and 3) movement of the cells through the dissolved barrier. This process can occur repeatedly and can result in metastases at sites distant from the original tumor.
  • the adhesion receptor integrin ⁇ v ⁇ 3 was identified as a marker of angiogenic blood vessels in chick and man and therefore such receptor plays a critical role in angiogenesis or neovascularization.
  • Angiogenesis is characterized by the invasion, migration and proliferation of smooth muscle and endothelial cells.
  • Antagonists of ⁇ v ⁇ 3 inhibit this process by selectively promoting apoptosis of cells in neovasculature.
  • the growth of new blood vessels, or angiogenesis also contributes to pathological conditions such as diabetic retinopathy and macular degeneration (Adonis et al., Amer. J. Ophthal., Vol.
  • ⁇ v ⁇ 3 antagonists would be useful therapeutic targets for treating such conditions associated with neovascularization (Brooks et al., Science, Vol. 264, (1994), 569-571 ).
  • ⁇ v ⁇ 3 is the major integrin on osteoclasts responsible for attachment to bone. Osteoclasts cause bone resorption and when such bone resorbing activity exceeds bone forming activity it results in osteoporosis (a loss of bone), which leads to an increased number of bone fractures, incapacitation and increased mortality. Antagonists of ⁇ v ⁇ 3 have been shown to be potent inhibitors of osteoclastic activity both in vitro [Sato et al., J. Cell. Biol., Vol. 111 (1990) 1713-1723] and in vivo [Fisher et al., Endocrinology, Vol. 132 (1993) 1411-1413].
  • Antagonism of ⁇ v ⁇ 3 leads to decreased bone resorption and therefore restores a normal balance of bone forming and resoround bottoming activity.
  • antagonists of osteoclast ⁇ v ⁇ 3 which are effective inhibitors of bone resorption and therefore are useful in the treatment or prevention of osteoporosis.
  • ⁇ v ⁇ 3 integrin in smooth muscle cell migration also makes it a therapeutic target for prevention or inhibition of neointimal hyperplasia which is a leading cause of restenosis after vascular procedures (Choi et al., J. Vase. Surg. Vol. 19(1) (1994) 125-34). Prevention or inhibition of neointimal hyperplasia by pharmaceutical agents to prevent or inhibit restenosis would be beneficial.
  • White Current Biology, Vol. 3(9)(1993) 596-599) has reported that adenovirus uses ⁇ v ⁇ 3 for entering host cells.
  • the integrin appears to be required for endocytosis of the virus particle and may be required for penetration of the viral genome into the host cell cytoplasm. Thus compounds which inhibit ⁇ v ⁇ 3 would find usefulness as antiviral agents.
  • the present invention relates to the following compounds:
  • R is H or alkyl; or pharmaceutically acceptable salts thereof.
  • the invention further involves treating or inhibiting pathological conditions associated therewith such as osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), angiogenesis, including tumor angiogenesis, retinopathy including diabetic retinopathy and macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis, smooth muscle cell migration and restenosis in a mammal in need of such treatment. Additionally, such pharmaceutical agents are useful as antiviral agents, and antimicrobials.
  • the present invention relates to a class of compounds represented by Formulae I-XVI, described above.
  • the invention further relates to pharmaceutical compositions containing therapeutically effective amounts of the compounds described above.
  • the invention also relates to a method of selectively inhibiting or antagonizing the ⁇ v ⁇ 3 integrin and more specifically relates to a method of inhibiting bone resorption, periodontal disease, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid
  • tumor growth neoplasia
  • angiogenesis including tumor angiogenesis
  • retinopathy including diabetic retinopathy and macular degeneration
  • arthritis including rheumatoid arthritis
  • smooth muscle cell migration and restenosis by administering a therapeutically effective amount of a compound described above to achieve such inhibition together with a pharmaceutically acceptable carrier.
  • alkyl or “lower alkyl” refer to a straight chain or branched chain hydrocarbon radicals having from about 1 to about 10 carbon atoms, and more preferably 1 to about 6 carbon atoms.
  • alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, neopentyl, hexyl, isohexyl, and the like.
  • halo or halogen refers to bromo, chloro, or iodo.
  • haloalkyl refers to alkyl groups as defined above substituted with one or more of the same or different halo groups at one or more carbon atom.
  • haloalkyl groups include trifluoromethyl, dichloroethyl, fluoropropyl and the like.
  • composition as used herein means a product which results from the mixing or combining of more than one element or ingredient.
  • pharmaceutically acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a chemical agent.
  • terapéuticaally effective amount shall mean that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or animal that is being sought by a researcher or clinician.
  • CH 3 CN acetonitrile
  • CHN analysis carbon/hydrogen/nitrogen elemental analysis
  • CHNCI analysis carbon/hydrogen/nitrogen/chlorine elemental analysis
  • CHNS analysis carbon/hydrogen/nitrogen/sulfur elemental analysis
  • DI water deionized water
  • FAB MS fast atom bombardment mass spectroscopy
  • g gram(s)
  • HOBT 1-hydroxybenzotriazole hydrate
  • KSCN potassium thiocyanate
  • LiOH lithium hydroxide
  • Na 2 SO 4 sodium sulfate
  • NMM N-methylmorpholine
  • NMP N-methyl pyrrolidinone
  • P2O5 phosphorous pentoxide
  • a bond drawn across a bond of a ring can be to any available atom on the ring.
  • pharmaceutically acceptable salt refers to a salt prepared by contacting a compound described above with an acid whose anion is generally considered suitable for human consumption.
  • examples of pharmacologically acceptable salts include the hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate, malate, succinate, tartrate salts and the like. All of the pharmacologically acceptable salts may be prepared by conventional means. (See Ber ⁇ e et al.. J Pharm. Sci.. 66(11. 1-19 (1977) for additional examples of pharmaceutically acceptable salts.)
  • compounds of the present invention may be administered orally, parenterally, or by inhalation spray, or topically in unit dosage formulations containing conventional pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes, for example, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intrape tonally.
  • the compounds of the present invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • Therapeutically effective doses of the compounds required to prevent or arrest the progress of or to treat the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.
  • the present invention provides a method of treating conditions mediated by selectively inhibiting or antagonizing the ⁇ v ⁇ 3 cell surface receptor which method comprises administering a therapeutically effective amount of a compound selected from the class of compounds described above, wherein one or more compounds is administered in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and if desired other active ingredients. More specifically, the present invention provides a method for inhibition of the ⁇ v ⁇ 3 cell surface receptor.
  • the present invention provides a method for inhibiting bone resorption, treating osteoporosis, inhibiting humoral hypercalcemia of malignancy, treating Paget's disease, inhibiting tumor metastasis, inhibiting neoplasia (solid tumor growth), inhibiting angiogenesis including tumor angiogenesis, treating diabetic retinopathy and macular degeneration, inhibiting arthritis, psoriasis and periodontal disease, and inhibiting smooth muscle cell migration including restenosis.
  • the compounds described above can be used in the treatment of patients suffering from the above pathological conditions.
  • selection of the most appropriate compound of the invention is within the ability of one with ordinary skill in the art and will depend on a variety of factors including assessment of results obtained in standard assay and animal models.
  • Treatment of a patient afflicted with one of the pathological conditions comprises administering to such a patient an amount of compound described above which is therapeutically effective in controlling the condition or in prolonging the survivability of the patient beyond that expected in the absence of such treatment.
  • inhibitory of the condition refers to slowing, interrupting, arresting or stopping the condition and does not necessarily indicate a total elimination
  • the compounds of the invention can be used in a variety of biological, prophylactic or therapeutic areas. It is contemplated that these compounds are useful in prevention or treatment of any disease state or condition wherein the ⁇ v ⁇ 3 integrin plays a role.
  • the dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 1000 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions, and more preferably from about 0.01 mg to about 100 mg per kg of body weight per day.
  • the active ingredient administered by injection is formulated as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.
  • a suitable daily dose would typically be about 0.01 to 10 mg kg body weight injected per day in multiple doses depending on the factors listed above.
  • the compounds in a therapeutically effective amount are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
  • the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, gelatin, acacia, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated for convenient administration.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium
  • compositions useful in the present invention may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional pharmaceutical adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.
  • Scheme I illustrates methodology useful for preparing the tetrahydropyrimidinobenzoic acid portion of the present invention which can be coupled to a gly- ⁇ -amino acid ester.
  • 3,5- dihydroxybenzoic acid is converted to 3-amino-5-hydroxy-benzoic acid using the procedure described in Austr. J. Chem.. 34 (6), 1319-24 (1981 ).
  • the product is reacted with ammonium thiocyanate in hot dilute hydrochloric acid to give 3-thiourea-5-hydroxybenzoic acid after normal work-up.
  • This thiourea intermediate is converted to the S-methyl derivative by reaction with methyl iodide in ethanol at reflux.
  • the HCI salt may be obtained by lyophilizing from dilute hydrochloric acid.
  • the product may be isolated from the original reaction mixture by removing volatiles and concentrating.
  • the resulting product is taken up in water and pH adjusted to about 5-7 where zwitterionic product precipitates and is isolated by filtration.
  • the HCI salt may be obtained as previously stated or by simply dissolving in dilute hydrochloric acid and concentrating to a solid and drying.
  • Scheme IA illustrates methodology useful for preparing the tetrahydropyrimidinobenzoic acid portion of the present invention which can be coupled to a gly- ⁇ -amino acid ester.
  • Scheme IA 3- diamino-2-hydroxypropane is reacted with carbon disulfide in an appropriate solvent such as ethanol - water, refluxed, cooled, hydrochloric acid added, refluxed again, cooled and the product, 5- hydroxytetrahydropyrimidine-2-thione harvested by filtration and dried.
  • This cyclic thiourea intermediate is converted to the S-methyl derivative by reaction of thione and methyl iodide in ethanol at reflux.
  • 2-methylthioether-5-hydroxypyhmidine hydroiodide is readily isolated by removing volatiles at reduced pressure.
  • 2-methylthioether-5- hydroxypyrimidine hydroiodide in methylene chloride : DMA (about 10:1 ) and an equivalent of triethylamnine are cooled to about ice-bath temperature and an equivalent of di-tert-butyl dicarbonate (BOC anhydride) added.
  • BOC anhydride di-tert-butyl dicarbonate
  • 3-amino-5-hydroxy- benzoic acid is converted to 3-amino-5-hydroxy- benzoic acid using the procedure of Aust. J. Chem., 34 (6), 1319-24 (1981 ).
  • the final desired product, 3-hydroxy-5-[(5-hydroxy-1 ,4,5,6- tetrahydro-2-pyrimidinyl)amino]benzoic acid hydrochloride salt is prepared by reacting BOC-2-methylthioether-5-hydroxypyrimidine and 3-amino-5- hydroxy-benzoic acid in hot DMA. Upon cooling, a precipitate forms and zwitterionic product isolated by filtration.
  • the HCI salt can be obtained by lyophilizing from dilute hydrochloric acid, for example.
  • Ya ⁇ d X are halo groups
  • 3-iodo-5-chlorosalicylaldehyde may be prepared by reacting 5-chlorosalicylaldehyde with N-iodosuccinimide in DMF and subjecting the reaction mixture to usual work-up conditions.
  • 3-iodo-5- bromosalicylaldehyde may be prepared by reacting 5- bromosalicylaldehyde in acetonitrile with potassium iodide and chloramine T. Work-up gives a material that when treated with hexanes gives the desired 3-iodo-5-chlorosalicylaldehyde.
  • Coumarins are readily prepared from salicylaldehydes using a modified Perkin reaction (e.g., Vogel's Textbook of Practical Organic Chemistry, 5th Ed., 1989, p. 1040, ) .
  • the halo-substituted coumarins are converted to 3-aminohydrocoumarins (see J.G. Rico. Tett. Let.. 1994. 35, 6599-6602) which are readily opened in acidic alcohol to give 3-amino-3- (3,5-halo-2-hydroxy)phenyl propanoic acid esters.
  • 3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters are converted to N-gly-3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters by reaction of Boc-N-gly-N-hydroxysuccinimide to give Boc-N-gly- 3- amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters that are converted to HX salts of N-gly- 3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters (wherein X is a halo group) for example, by removal of the BOC-protecting group using HCI in ethanol.
  • amino acid compounds used in preparing the compounds of the present invention can be prepared according to the procedures set forth
  • Y and X are halo groups
  • the product is purified by prep hplc and the ester hydrolyzed to the acid by treating with a base, such as LiOH in a suitable solvent (dioxane/water or acetonitrile/water).
  • a suitable acid such as TFA can be used.
  • the product is isolated by prep hplc or by isolating the zwitterion at pH 5-7 and converting to the desired salt by standard procedures.
  • the temperature was maintained below 0°C overnight.
  • the reaction mixture was concentrated to about one-half its original volume and partitioned between EtOAc (3 L) and water (2L).
  • the organic layer was washed with aqueous HCI (3 x 1 L 0.5 N HCI).
  • the pH of the combined aqueous layers was adjusted to about 7 by addition of 10% aqueous NaOH and extracted with methylene chloride (3 x 2L).
  • the combined organic layers were dried (MgSO 4 ), filtered, and 4M HCI in dioxane (210 mL) added with stirring. Upon completion of precipitation the solid was removed by filtration.
  • the filtrate was concentrated to a small volume and methyl t-butyl ether added.
  • the solid obtained was combined with the initially formed solid and the combined product was washed with
  • N-t-Boc-glycine N-hydroxysuccinimide ester (Sigma, 15.0 g, 0.055 mol), dry DMF (Aldrich Sure Seal, 200 mL) and the product from Step 2 (21.67 g, 0.055 mol) under an inert atmosphere (Ar).
  • the reaction mixture was cooled to approximately 0°C (salt-ice bath) and N- methylmorpholine (5.58 g, 0.056 mole) and a catalytic amount of DMAP added and the reaction allowed to proceed overnight.
  • the reaction mixture was concentrated to a slush, and partitioned between EtOAc (0.4L) and aqueous base (2 x 0.2 L, aqueous saturated NaHCOs).
  • the organic layer was washed consecutively with aqueous citric acid (2 x 0.2 L, 10% w/v), again with aqueous sodium bicarbonate (2 x 0.2 L), brine and dried (Na 2 S0 4 ). Volatiles were removed under vacuum at 55°C to give an oil (22.5 g, 92% yield) that solidified on standing.
  • Step 3 The product obtained in Step 3 was de-protected to give the amine hydrochloride salt using the following procedure.
  • N-t-Boc-glycine N-hydroxysuccinimide ester (Sigma, 2.72 g, 0.010 mol)
  • dry THF Aldrich Sure Seal, 50 mL
  • the product from Step 3 (3.10 g, 0.01 mole, vacuum desiccated overnight over P 2 0 5 ) under an inert atmosphere (Ar).
  • the reaction mixture was cooled to approximately OX (salt-ice bath) and triethylamine (1.01 g, 0.010 mole) was added. The reaction was allowed to proceed overnight.
  • the reaction mixture was concentrated to a semi-solid and worked up in a fashion similar to Example A, Step 3. Volatiles were removed from the organic layer under vacuum at 55X to give an oil (4 g, 83% yield) that solidified on standing.
  • Step 4 The product obtained in Step 4 was de-protected to give the amine hydrochloride salt using the following procedure.
  • N-t-Boc-glycine N-hydroxysuccinimide ester (Sigma, 8.1 g, 0.030 mol)
  • dry DMF Aldrich Sure Seal, 50 mL
  • the product of Step 3 (12 g, 0.03 mole, vacuum desiccated overnight over P 2 O 5 ) under an inert atmosphere (Ar).
  • the reaction mixture was cooled to approximately OX (salt-ice bath) and N-methyl morpholine (3.03 g, 0.030 mole) and catalytic DMAP added. The reaction was allowed to proceed overnight warming to room temperature.
  • Step 4 The product obtained in Step 4 was deprotected to give the amine hydrochloride salt using the following procedure.
  • N-lodosuccinimide 144.0 g, 0.641 mole was added to a solution of 5-chlorosalicylaldehyde (100 g, 0.638 mole) in dimethylformamide (400 mL). The reaction mixture was stirred for 2 days at room temperature. Additional N-iodosuccinimide (20.0 g) was added and the stirring was continued for an additional 2 days.
  • reaction mixture was diluted with ethyl acetate (1 L), washed with hydrochloric acid (300 mL, 0.1 N), water (300 mL), sodium thiosulfate (5%, 300 mL), brine (300 mL), dried (MgSO 4 ) and was concentrated to dryness to afford the desired aldehyde (162 g, 90% yield) as a pale yellow solid.
  • Lithium hexamethyldisilazane (21.62 mL, 1M, 21.62 mmol) was added to a solution of 6-chloro-8-iodocoumarin (6.63 g, 21.62 mmol) in tetrahydrofuran (100 mL) at -78X.
  • the reaction mixture was stirred at this 5 temperature for 30 minutes, then at OX for 1 hour.
  • Acetic acid (1.3 g, 21.62 mmol) was added to the reaction mixture.
  • the reaction mixture was poured into ethyl acetate (300 mL) and saturated sodium carbonate (200 mL) solution.
  • Ethanol (375 mL) and deionized water (375 mL) were added to a 2L 3-neck round bottom flask fitted with a mechanical stirrer, Claisen adapter, addition funnel, reflux condenser and thermocouple.
  • 1 ,3- diamino-2- hydroxypropane (125.04 g, 1.39 mol) (Aldrich) was added to the reaction flask and stirred to dissolve.
  • Carbon disulfide (84 mL , 1.39 mol) was added in a drop-wise fashion via addition funnel at 25-33X over a 35 minute period to afford a milky-white mixture. The temperature was maintained with an ice bath.
  • the reaction mixture was refluxed at 73.4X for two hours to afford a yellow solution.
  • the reaction mixture was cooled with an ice bath to 25X and concentrated HCI (84 mL) was added in drop- wise fashion while maintaining the temperature at 25-26X.
  • the reaction mixture was refluxed for 21 hours at 78.4X.
  • the reaction solution was cooled to 2X and product collected via vacuum filtration.
  • the white solid was washed 3 times with ice bath chilled ethanol : water (1 :1 ) (50 mL) and dried in vacuo at 40X to afford 5-hydroxytetrahydropyrimidine-2-thione (63.75 g, 34.7% yield) as a white solid.
  • Step 1 absolute ethanol (570 mL), and methyl iodide (45 mL , 0.72 mol) were added to a 2 L round bottom flask fitted with a mechanical strirrer and thermocouple. The reaction mixture was refluxed at 78X for 5 hours and then cooled to room temperature. The reaction mixture was concentrated
  • 2-Methyl thioether-5-hydroxypyrimidine hydroiodide 150.81 g, 0.55 mol
  • methylene chloride 530 mL
  • dimethylacetamide 53 mL
  • triethylamine 76.7 mL, 0.55 mol
  • the mixture was cooled with an ice bath and di- tert -butyl dicarbonate (120.12 g, 0.55 mol) was added at 4X.
  • the reaction mixture was heated at 42.5X for 18 hours to afford a light yellow solution.
  • reaction solution was transferred to a 2L separatory funnel and washed 3 times with DI water (200 mL), dried with MgS0 4 , filtered and concentrated in vacuo to afford Boc-2-methylthioether-5-hydroxypyrimidine (134.6 g, 99.35% yield) as a light yellow viscous oil. MS and H NMR were consistent with the desired structure.
  • Boc-2-methylthioether-5-hydroxypyrimidine (50.3 g, 0.204 mol), 3- amino-5-hydroxybenzoic acid (Aust. J. Chem. (1981 ) 34(6), 1319-24) (25.0 g, 0.1625 mole) and 50 mL anhydrous DMA were heated at 100X with stirring for 2 days. A slurry precipitate resulted. The reaction was cooled to room temperature and the precipitate was filtered, washed with CH 3 CN, then ethyl ether and dried. This solid was slurried in H 2 O and acidified with concentrated HCI resulting in a solution. This was frozen and lyophilized to yield the desired product as a white solid (14.4 g). MS and 1 H NMR were consistent with the desired structure.
  • the mixture was cooled to 50X before charging tert-butyl bromoacetate (488 g, 369 mL, 2.5 mol) via 50 mL syringe and syringe pump (delivery set to 4.1 mlJminutes) over 1.5 hours. Reaction temperature of 50° +/- 5X was maintained throughout the addition. The reaction mixture was allowed to stir at 50X for one hour after the addition was complete. Subsequently, the mixture was allowed to cool to 25X and the precipitated product allowed to settle. The THF mother liquor was decanted into a 2-L round bottom flask using a coarse fritted filter stick and partial vacuum transfer (20 mm Hg). This removed about 65% of the THF from the mixture. 1- Methyl-2-pyrrolidinone (NMP, 800 mL) was added and agitation resumed for 5 minutes. The reaction mixture can be filtered to remove any remaining zinc. Analysis indicated a titer of desired Reformatsky reagent
  • the solid reagent can be isolated by filtration from the original reaction mixture.
  • the cake can be washed with THF until a white solid is obtained and dried under N 2 to obtain the desired product as a mono THF solvate that may be stored at - 20X (desiccated) for extended periods. Typical recoveries are 85-90%.
  • Potassium carbonate (powder, oven dried at 100X under vacuum, 8.82 g, 60 mmoles) was added to a solution of 3,5-dichlorosalicylaldehyde (11.46 g, 60 moles) in DMF (40 mL) at room temperature to give a bright yellow slurry.
  • MEMCI (neat, 7.64 g, 61 mmoles) was then added while maintaining the bath temperature at 20X. The mixture was then stirred at 22X for 6 hours and MEMCI (0.3 g, 2.4 mmoles) was added. The mixture was stirred for another 0.5 hour and the reaction mixture poured into cold water (200 mL) to precipitate the product.
  • the Boc-protected glycine amide prepared in Step 4 (27.0 g, 0.062 mole) was dried overnight over P 2 O 5 and NaOH pellets. The solid was dissolved in dioxane (40 mL) and the solution cooled to OX. An equivalent volume of 4N HCI/dioxane (0.062 mole) was added and the reaction was run for 2 hours. At this point the conversion was 80% by RPHPLC. The reaction mixture was allowed to warm to room temperature
  • Potassium carbonate (powder, oven dried at 100X under vacuum, 22.1g, 0.16 moles) was added to a solution of 3-chloro-5- bromosalicylaldehyde (35.0 g, 0.15 moles) in DMF (175 ml) at room temperature to give a bright yellow slurry.
  • MEMCI (neat, 25.0 g, 0.2 moles) was then added while maintaining the bath temperature at 20X. The mixture was then stirred at 22X for 6 hours and was poured into DI water (1200mL) to precipitate the product. The slurry was filtered on a pressure filter and the cake was washed with DI water (2 x 400 mL) and was dried under N 2 /vacuum to afford the product (46.
  • Example I The above compound was prepared according to the procedures outlined in Example I, Step 4 and Step 5 where an equivalent quantity of the intermediate prepared in Step 5 as the free base is substituted fin Example I, Step 4.
  • N-lodosuccinimide 144.0 g, 0.641 mole was added to a solution of 5-chlorosalicylaldehyde (100 g, 0.638 mole) in dimethylformamide (400 mL). The reaction mixture was stirred for 2 days at room temperature. Additional N-iodosuccinimide (20.0 g) was added and stirring was continued for additional 2 days.
  • reaction mixture was diluted with ethyl acetate (1L), washed with hydrochloric acid (300 mL, 0.1 N), water (300 mL), sodium thiosulfate (5%, 300 mL), brine (300 mL), dried (MgSO 4 ) and was concentrated to dryness to afford the desired aldehyde as a pale yellow solid (162 g, 90% yield).
  • Example I The above compound is prepared according to the procedure of Example I by substituting an equivalent amount of 3-iodo-5- bromosalicylaldehyde prepared in Example F, Step 1 for 3,5- dichlorosalicylaldehyde in Example I, Step 2 A.
  • Example B (0.58 g, 0.0014 mole), triethylamine (0.142 g, 0.0014 mole), DMAP (17 mg), and anhydrous DMA (4 ml) was added EDCI (0.268 g, 0.0014 mole) at ice bath temperature. The reaction was stirred overnight at room temperature. The resulting ester intermediate was isolated by reverse phase preparatory HPLC. To this ester in H 2 O (10 ml) and CH 3 CN (5 ml) was added LiOH (580 mg, 0.0138 mole). After stirring at room temperature for 1 hour, the pH was lowered to 2 with TFA and the product was purified by reverse phase preparatory HPLC to yield (after lyophilization) the desired product as a white solid (230 mg). MS and 1 H NMR were consistent with the desired structure.
  • Example 2 The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product from Example A for the product from Example B. The yield, after lyophiiization was 320 mg of as a white solid. MS and 1 H NMR were consistent with the desired structure.
  • Example 1 The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product from Example F for the product from Example B. The yield (after lyophiiization) was 180 mg as a white solid. MS and 1 H NMR were consistent with the desired structure.
  • Example 2 The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product of Example D for the product of Example B. The yield (after lyophiiization) was 180 mg as a white solid. MS and 1 H NMR were consistent with the desired structure.
  • Example 2 The above compound was prepared according to the methodology of Example 1, substituting an equivalent amount of the product from Example E for the product from Example B. The yield (after lyophiiization) was 250 mg as a white solid. MS and 1 H NMR were consistent with the desired structure.
  • Example 2 The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product from Example C for the product from Example B. The yield (after lyophiiization) was 220 mg as a white solid. MS and ⁇ NMR were consistent with the desired product.
  • Example H To the product from Example H (7.8 g, 0.027 mole) dissolved in anhydrous DMA (50 mL) in a flame dried flask under N 2 and at ice bath temperature was slowly added isobutylchloroformate (3.7 g, 0.027 mole) followed by N-methylmorphoiine (2.73 g, 0.027 mole). The solution was stirred at ice bath temperature for 15 minutes. To the reaction mixture was then added the product from Example L (10.0 g, 0.024 mole) at ice bath temperature followed by N-methylmorpholine (2.43 g, 0.024 mole). The reaction was then stirred at room temperature overnight. The resulting ester intermediate was isolated by reverse phase prep HPLC.
  • Step A To the product from Example H (9.92 g, 0.0345 mole) dissolved in anhydrous DME (200 mL) is added N-methylmorpholine (4.0 mL, 0.0362 mole). The reaction mixture was cooled to -5X (salt-ice bath). Isobutylchloroformate, IBCF (4.48 mL, 4.713 g, 0.0345 mole) was added over one minute and the reaction mixture stirred at ice bath temperature for 12 minutes. To the reaction mixture was then added the product from Example I (11.15 g, 0.030 mole) at ice bath temperature followed by N- methylmorpholine (4.0 mL, 0.0362 mole).
  • the product produced in Step A (about 11 g) was dissolved in dioxane : water and the pH of the solution adjusted to approximately 11.5 (pH meter) by the addition of 2.5 N NaOH.
  • the reaction mixture was stirred at room temperature. Periodically, the pH was re-adjusted to > 11 by further addition of base. After 2-3 hours the conversion of ester to acid was deemed complete by RPHPLC.
  • the pH of the reaction mixture was adjusted to about 6 and a viscous oil precipitated from solution. The oil was isolated by decantation and washed with hot water (200 mL). The resulting aqueous mixture was allowed to cool and the solid was collected by filtration to yield The above compound (2.6 g after lyophiiization from HCI solution). The residue, which was a dark viscous oil was treated with hot water to give on cooling a tan powder (4.12 g after lyophiiization from HCI solution). MS and 1 H NMR were consistent with the desired structure.
  • Step 2 The product of Step 2 was dissolved in a suitable solvent
  • Example 8 The above compound was prepared using the procedure of Example 8 substituting the product of Example N for the product of Example I in Example 8, Step A.
  • the product was isolated by prep RPHPLC and lyophilized to give the desired product as a TFA salt.
  • Example 8 The above compound was prepared using essentially the procedures of Example 8 and substituting the product of Example M for the product of Example I in Example 8, Step A.
  • the product was isolated by preparatory RPHPLC and lyophilized to give the desired product as a TFA salt.
  • Example 8 The above compound was prepared using the procedures of Example 8 and substituting the product of Example P for the product of Example I in Example 8, Step A.
  • the product is isolated by prep RPHPLC and lyophilized to give the desired product as a TFA salt.
  • Step 6 A solution of m-(5-hydroxypyrimidino)hippuric acid (3.74 g, 12.98 mmol) in dimethylacetamide (25 mL) was heated until all the material had dissolved. This was then cooled to OX and isobutylchloroformate (1.68 mL) was added in one portion followed by N-methylmorpholine (1.45 mL). After 10 minutes, ethyl 3-(N-gly)-amino-3-(3,5-diiodo-2-hydroxyphenyl)- propionate hydrochloride (6.0 g, 10.82 mmol) was added in one portion followed by N-methylmorpholine (1.45 mL). The reaction mixture was stirred for 18 hours at room temperature.
  • reaction mixture was concentrated, the residue dissolved in tetrahydrofuran/water (1 :1 , 20mL), and was chromatographed (reverse phase, 95:5 water: acetonitrile over 60 minutes to 30:70 water: acetonitrile containing 0.1 % TFA). The combined fractions were concentrated. The residue was dissolved in acetonitrile water and lithium hydroxide was added until basic. The solution was stirred for 2 hours. The reaction mixture was concentrated and was
  • Human vitronectin receptor ( ⁇ v ⁇ s) was purified from human placenta as previously described [Pytela et al., Methods in Enzvmolo ⁇ v. 1 4:475- 489 (1987)]. Human vitronectin was purified from fresh frozen plasma as previously described [Yatohgo et al., Cell Structure and Function. 13:281 - 292 (1988)]. Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to purified vitronectin as previously described [Charo et al., J. Biol. Chem., 266(3):1415-1421 (1991 )].
  • Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO).
  • Anti-biotin antibody was obtained from Calbiochem (La Jolla, CA). Linbro microtiter plates were obtained from Flow Labs (McLean, VA).
  • ADP reagent was obtained from Sigma (St. Louis, MO).
  • TBS +++ /BSA as the diluent.
  • This premixing of labeled ligand with test (or control) ligand, and subsequent transfer of 50 L aiiquots to the assay plate was carried out with a CETUS Propette robot; the final concentration of the labeled ligand was 1 nM and the highest concentration of test compound was 1.0 x 10 " M.
  • the competition occurred for two hours after which all wells were washed with a plate washer as before.
  • Affinity purified horseradish peroxidase labeled goat anti-biotin antibody was diluted 1 :3000 in TBS +++ /BSA and 125 L were added to each well.
  • the plates were washed and incubated with OPD/H 2 O substrate in 100 mM/L Citrate buffer, pH 5.0.
  • the plate was read with a microtiter plate reader at a wavelength of 450 nm and when the maximum-binding control wells reached an absoround bottomance of about 1.0, the final A 450 were recorded for analysis.
  • the data were analyzed using a macro written for use with the EXCEL spreadsheet program.
  • the mean, standard deviation, and %CV were determined for duplicate concentrations.
  • the mean A 450 values were normalized to the mean of four maximum-binding controls (no competitor added)(B-MAX).
  • Example 1 which is a potent ⁇ v ⁇ 3 antagonist (IC 50 in the range 3-10 nM) was included on each plate as a positive control.
  • Human fibrinogen receptor ( ⁇ n b ⁇ 3) was purified from outdated platelets. (Pytela, R., Pierschbacher, M.D., Argraves, S., Suzuki, S., and Rouslahti, E. "Arginine-Glycine-Aspartic acid adhesion receptors", Methods in Enzvmology 144(1987):475-489.) Human vitronectin was purified from fresh frozen plasma as described in Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M., "Novel purification of vitronectin from human plasma by heparin affinity chromatography," Cell Structure and Function 13(1988):281-292.
  • Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to purified vitronectin as previously described.
  • NHS-biotin from Pierce Chemical Company (Rockford, IL)
  • purified vitronectin as previously described.
  • Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO).
  • Anti-biotin antibody was obtained from Calbiochem (La Jolla, CA). Linbro microtiter plates were obtained from Flow Labs (McLean, VA).
  • ADP reagent was obtained from Sigma (St. Louis, MO).
  • the diluted receptor was immediately transferred to Linbro microtiter plates at 100 ⁇ Uwell (100 ng receptor/well). The plates were sealed and incubated overnight at 4X to allow the receptor to bind to the wells. All remaining steps were at room temperature. The assay plates were emptied and 200 ⁇ L of 1 % RIA grade BSA in TBS +++ (TBS +++ /BSA) were added to block exposed plastic surfaces. Following a 2 hour incubation, the assay plates were washed with TBS +++ using a 96 well plate washer.
  • Affinity purified horseradish peroxidase labeled goat anti-biotin antibody was diluted 1 :3000 in TBS +++ /BSA and 125 ⁇ L were added to each well. After 30 minutes, the plates were washed and incubated with ODD/H 2 O 2 substrate in 100 mM/L citrate buffer, pH 5.0. The plate was read with a microtiter plate reader at a wavelength of 450 nm and when the maximum-binding control wells reached an absoround bottomance of about 1.0, the final A450 were recorded for analysis. The data were analyzed using a macro written for use with the EXCELTM spreadsheet program. The mean, standard deviation, and %CV were determined for duplicate concentrations.
  • the mean A 450 values were normalized to the mean of four maximum-binding controls (no competitor added)(B-MAX).
  • the normalized values were subjected to a four parameter curve fit algorithm, [Robard et al., Int. Atomic Energy Agency. Vienna, pp 469 (1977)], plotted on a semi-log scale, and the computed concentration corresponding to inhibition of 50% of the maximum binding of biotinylated vitronectin (IC50) and corresponding R 2 was reported for
  • Healthy aspirin free donors were selected from a pool of volunteers.
  • the harvesting of platelet rich plasma and subsequent ADP induced platelet aggregation assays were performed as described in Zucker, M.B., "Platelet Aggregation Measured by the Photometric Method", Methods in Enzvmoloov 169(1989):117-133.
  • Standard venipuncture techniques using a butterfly allowed the withdrawal of 45 mL of whole blood into a 60 mL syringe containing 5 mL of 3.8% trisodium citrate.
  • the anti-coagulated whole blood was transferred to a 50 mL conical polyethylene tube.
  • the blood was centrifuged at room temperature for 12 minutes at 200 mg to sediment non-platelet cells.
  • Platelet rich plasma was removed to a polyethylene tube and stored at room temperature until used. Platelet poor plasma was obtained from a second centrifugation of the remaining blood at 2000 xg for 15 minutes. Platelet counts are typically 300,000 to 500,000 per microtiter. Platelet rich plasma (0.45 mL) was aliquoted into siliconized cuvettes and stirred (1100 rpm) at 37X for 1 minute prior to adding 50 uL of pre-diluted test compound. After 1 minute of mixing, aggregation was initiated by the addition of 50 uL of 200 uM ADP. Aggregation was recorded for 3 minutes in a Payton dual channel aggregometer (Payton Scientific, Buffalo, NY).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention is directed to compounds of formula (1) and pharmaceutically acceptable salts and isomers thereof useful as αvβ3 integrin antagonists.

Description

META-AZACYCLIC AMINO BENZOIC ACID COMPOUNDS AND DERIVATIVES THEREOF BEING INTGRIN ANTAGONISTS
Field of the Invention The present invention relates to pharmaceutical agents (compounds) which are useful as αvβ3 integrin antagonists and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by avp3 by inhibiting or antagonizing αvβs integrins.
Background of the Invention Integrins are a group of cell surface glycoproteins which mediate cell adhesion and therefore are useful mediators of cell adhesion interactions which occur during various biological processes. Integrins are heterodimers composed of noncovalently linked α and β polypeptide subunits. Currently eleven different α subunits have been identified and six different β subunits have been identified. The various α subunits can combine with various β subunits to form distinct integrins.
The integrin identified as αvβ3 (also known as the vitronectin receptor) has been identified as an integrin which plays a role in various conditions or disease states including tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, including macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration (e.g. restenosis). Additionally, it has been found that such agents would be useful as antivirals, antifungals and antimicrobials. Thus, compounds which selectively inhibit or antagonize αvβ3 would be beneficial for treating such conditions. It has been shown that the αvβ3 integrin and other αv containing integrins bind to a number of Arg-Gly-Asp (RGD) containing matrix macromolecules. Compounds containing the RGD sequence mimic extracellular matrix ligands so as to bind to cell surface receptors. However, it is also known that RGD peptides in general are non-selective for RGD dependent integrins. For example, most RGD peptides which bind to αvβs also bind to αvβ5, αvβι and αιιbβ3. Antagonism of platelet αHbβ3 (also known as the fibrinogen receptor) is known to block platelet aggregation in humans. In order to avoid bleeding side-effects when treating the conditions or disease states associated with the integrin αvβ3, it would be beneficial to develop compounds which are selective antagonists of αvβ3 as opposed to αnbβ3.
Tumor cell invasion occurs by a three step process: 1) tumor cell attachment to extracellular matrix; 2) proteoiytic dissolution of the matrix; and 3) movement of the cells through the dissolved barrier. This process can occur repeatedly and can result in metastases at sites distant from the original tumor.
Seftor et al. (Proc. Natl. Acad. Sci. USA, Vol. 89 (1992) 1557-1561 ) have shown that the αvβ3 integrin has a biological function in melanoma cell invasion. Montgomery et al., (Proc. Natl. Acad. Sci. USA, Vol. 91 (1994) 8856-60) have demonstrated that the integrin αvβ3 expressed on human melanoma cells promotes a survival signal, protecting the cells from apoptosis. Mediation of the tumor cell metastatic pathway by interference with the αvβ3 integrin cell adhesion receptor to impede tumor metastasis would be beneficial.
Brooks et al. (Cell, Vol. 79 (1994) 1157-1164) have demonstrated that antagonists of αvβ3 provide a therapeutic approach for the treatment of neoplasia (inhibition of solid tumor growth) since systemic administration of αvβ3 antagonists causes dramatic regression of various histologically distinct human tumors.
The adhesion receptor integrin αvβ3 was identified as a marker of angiogenic blood vessels in chick and man and therefore such receptor plays a critical role in angiogenesis or neovascularization. Angiogenesis is characterized by the invasion, migration and proliferation of smooth muscle and endothelial cells. Antagonists of αvβ3 inhibit this process by selectively promoting apoptosis of cells in neovasculature. The growth of new blood vessels, or angiogenesis, also contributes to pathological conditions such as diabetic retinopathy and macular degeneration (Adonis et al., Amer. J. Ophthal., Vol. 118, (1994) 445-450) and rheumatoid arthritis (Peacock et al., J. Exp. Med., Vol. 175, (1992), 1135-1138). Therefore, αvβ3 antagonists would be useful therapeutic targets for treating such conditions associated with neovascularization (Brooks et al., Science, Vol. 264, (1994), 569-571 ).
It has been reported that the cell surface receptor αvβ3 is the major integrin on osteoclasts responsible for attachment to bone. Osteoclasts cause bone resorption and when such bone resorbing activity exceeds bone forming activity it results in osteoporosis (a loss of bone), which leads to an increased number of bone fractures, incapacitation and increased mortality. Antagonists of αvβ3 have been shown to be potent inhibitors of osteoclastic activity both in vitro [Sato et al., J. Cell. Biol., Vol. 111 (1990) 1713-1723] and in vivo [Fisher et al., Endocrinology, Vol. 132 (1993) 1411-1413]. Antagonism of αvβ3 leads to decreased bone resorption and therefore restores a normal balance of bone forming and resoround bottoming activity. Thus it would be beneficial to provide antagonists of osteoclast αvβ3 which are effective inhibitors of bone resorption and therefore are useful in the treatment or prevention of osteoporosis.
The role of the αvβ3 integrin in smooth muscle cell migration also makes it a therapeutic target for prevention or inhibition of neointimal hyperplasia which is a leading cause of restenosis after vascular procedures (Choi et al., J. Vase. Surg. Vol. 19(1) (1994) 125-34). Prevention or inhibition of neointimal hyperplasia by pharmaceutical agents to prevent or inhibit restenosis would be beneficial. White (Current Biology, Vol. 3(9)(1993) 596-599) has reported that adenovirus uses αvβ3 for entering host cells. The integrin appears to be required for endocytosis of the virus particle and may be required for penetration of the viral genome into the host cell cytoplasm. Thus compounds which inhibit αvβ3 would find usefulness as antiviral agents.
Summary of the Invention The present invention relates to compound of the following general formula
H
Figure imgf000006_0001
X ^ Y wherein X and Y are the same or different halo group and pharmaceutically acceptable salts thereof.
The compounds described above can exist in various isomeric forms and all such isomeric forms are meant to be included. Tautomeric forms are also included as well as pharmaceutically acceptable salts of such isomers and tautomers.
More specifically, the present invention relates to the following compounds:
O
H H π H
Figure imgf000006_0002
HO— H ° - ' 0)
OH
Br
(D)
HCT
Figure imgf000006_0003
H H rV : (HI)
Figure imgf000007_0001
OH
Br
Figure imgf000007_0002
CO2R
OH ; (n
Figure imgf000007_0003
Cl
: 00
Figure imgf000007_0004
'• (VI)
Figure imgf000007_0005
"CO2R
-N OH : (vπ)
HO'
OH
'Cl CO2R
OH ; (Nm)
Figure imgf000008_0001
Br
H H
CO2R OH : (IX)
HO
Figure imgf000008_0002
Figure imgf000008_0003
OH
H H
,N N N
N-^γ γ^CO2R
II
,N H " 1 OH : (X)
HO'
Figure imgf000008_0004
OH
Br'
O
H H H
Figure imgf000008_0005
V^CO2R
O .OH (XI)
H - N
, O'
OH
*CI
O
H ,N.
CO2R
-N OH ; (xπ)
HO'
OH
Figure imgf000008_0006
Br pan)
Figure imgf000009_0001
N ΓMHΠ__
*C02R ; P^V)
Figure imgf000009_0002
Figure imgf000009_0003
; (XV) and
Figure imgf000009_0004
*CO2R
^ , (XVD
OH
Figure imgf000009_0005
wherein R is H or alkyl; or pharmaceutically acceptable salts thereof.
It is another object of the invention to provide pharmaceutical compositions comprising compounds described above. Such compounds and compositions are useful in selectively inhibiting or antagonizing the integrin and therefore in another embodiment the present invention relates to a method of selectively inhibiting or antagonizing the αvβ3 integrin. The invention further involves treating or inhibiting pathological conditions associated therewith such as osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), angiogenesis, including tumor angiogenesis, retinopathy including diabetic retinopathy and macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis, smooth muscle cell migration and restenosis in a mammal in need of such treatment. Additionally, such pharmaceutical agents are useful as antiviral agents, and antimicrobials.
Detailed Description
The present invention relates to a class of compounds represented by Formulae I-XVI, described above.
Preferred embodiments of the present invention are compounds of the following formulae
; p VH)
Figure imgf000010_0001
; (xNm)
Figure imgf000010_0002
H H
N' 'CO2H
H OH '• ^
HO
Figure imgf000011_0001
Figure imgf000011_0002
OH
Br'
- H
'C02H
-N
Figure imgf000011_0003
y O OH ; (XX)
HO'v
OH
Br'
- Hv .N I OO)
HO'
Figure imgf000011_0004
OH
Figure imgf000011_0005
C02H
OH ; P∞1)
Figure imgf000011_0006
Br
O
H
Figure imgf000011_0008
'CO2H
Figure imgf000011_0007
_N O OH ; (xxm)
HO'
OH H H
CO2H
Figure imgf000012_0002
0H ; pσσv)
,N
HO' -v
Figure imgf000012_0001
OH
'Br
H H
)
HO' -v N' CO2H H
.N OH : 0
Figure imgf000012_0003
OH
CO2H
0H ; (XXVI)
Figure imgf000012_0004
O
H H
Figure imgf000012_0005
NH_
XO2H
-N O 0H ; (xxvπ)
HO'
OH
Cl' I
O
H
Figure imgf000012_0007
CO2H
Figure imgf000012_0006
,N 0H ; pσvm)
HO'
OH
Figure imgf000012_0009
cr
10 ; ( OX)
Figure imgf000013_0001
; (XXX)
Figure imgf000013_0002
; (XXXI) and
Figure imgf000013_0003
• (XXXII)
Figure imgf000013_0004
The invention further relates to pharmaceutical compositions containing therapeutically effective amounts of the compounds described above.
The invention also relates to a method of selectively inhibiting or antagonizing the αvβ3 integrin and more specifically relates to a method of inhibiting bone resorption, periodontal disease, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid
1 1 tumor growth (neoplasia), angiogenesis, including tumor angiogenesis, retinopathy including diabetic retinopathy and macular degeneration, arthritis, including rheumatoid arthritis, smooth muscle cell migration and restenosis by administering a therapeutically effective amount of a compound described above to achieve such inhibition together with a pharmaceutically acceptable carrier.
The following is a list of definitions of various terms used herein:
As used herein, the terms "alkyl" or "lower alkyl" refer to a straight chain or branched chain hydrocarbon radicals having from about 1 to about 10 carbon atoms, and more preferably 1 to about 6 carbon atoms. Examples of such alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, neopentyl, hexyl, isohexyl, and the like.
As used herein the term "halo" or "halogen" refers to bromo, chloro, or iodo.
As used herein the term "haloalkyl" refers to alkyl groups as defined above substituted with one or more of the same or different halo groups at one or more carbon atom. Examples of haloalkyl groups include trifluoromethyl, dichloroethyl, fluoropropyl and the like. The term "composition" as used herein means a product which results from the mixing or combining of more than one element or ingredient.
The term "pharmaceutically acceptable carrier", as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a chemical agent.
The term "therapeutically effective amount" shall mean that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or animal that is being sought by a researcher or clinician.
The following is a list of abbreviations and the corresponding meanings as used interchangeably herein:
12 1H-NMR = proton nuclear magnetic resonance
AcOH = acetic acid
Ar = argon
CH3CN = acetonitrile CHN analysis = carbon/hydrogen/nitrogen elemental analysis
CHNCI analysis = carbon/hydrogen/nitrogen/chlorine elemental analysis
CHNS analysis = carbon/hydrogen/nitrogen/sulfur elemental analysis DI water = deionized water
DMA = N.N-dimethylacetamide
DMAP = 4-(ϋ,N-dimethylamino)pyridine
DMF = N,N-dimethylformamide
EDCI = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
EtOAc = ethyl acetate
EtOH = ethanol
FAB MS = fast atom bombardment mass spectroscopy g = gram(s) HOBT = 1-hydroxybenzotriazole hydrate
HPLC = high performance liquid chromatography
IBCF = isobutylchloroformate
KSCN = potassium thiocyanate
L = liter LiOH = lithium hydroxide
MEM = methoxyethoxymethyl
MEMCI = methoxyethoxymethyl chloride
MeOH = methanol mg = milligram MgSO4 = magnesium sulfate ml = milliliter mL = milliliter
MS = mass spectroscopy
MTBE = methyl tert-butyl ether N2 = nitrogen
NaHC03 = sodium bicarbonate
NaOH = sodium hydroxide
Na2SO4 = sodium sulfate
NMM = N-methylmorpholine NMP = N-methyl pyrrolidinone
NMR = nuclear magnetic resonance
P2O5 = phosphorous pentoxide
PTSA = para-toluenesulfonic acid
RPHPLC = reverse phase high performance liquid chromatography
RT = room temperature
TFA = trifluoroacetic acid
THF = tetrahydrofuran
13 TMS = trimethylsilyl
Δ = heating the reaction mixture
The compounds described above can exist in various isomeric forms and all such isomeric forms are meant to be included. Tautomeric forms are also included as well as pharmaceutically acceptable salts of such isomers and tautomers.
In the structures and formulas herein, a bond drawn across a bond of a ring can be to any available atom on the ring. The term "pharmaceutically acceptable salt" refers to a salt prepared by contacting a compound described above with an acid whose anion is generally considered suitable for human consumption. Examples of pharmacologically acceptable salts include the hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate, malate, succinate, tartrate salts and the like. All of the pharmacologically acceptable salts may be prepared by conventional means. (See Berαe et al.. J Pharm. Sci.. 66(11. 1-19 (1977) for additional examples of pharmaceutically acceptable salts.)
For the selective inhibition or antagonism of αvβ3 integrins, compounds of the present invention may be administered orally, parenterally, or by inhalation spray, or topically in unit dosage formulations containing conventional pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes, for example, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intrape tonally.
The compounds of the present invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds required to prevent or arrest the progress of or to treat the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.
14 Accordingly, the present invention provides a method of treating conditions mediated by selectively inhibiting or antagonizing the αvβ3 cell surface receptor which method comprises administering a therapeutically effective amount of a compound selected from the class of compounds described above, wherein one or more compounds is administered in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and if desired other active ingredients. More specifically, the present invention provides a method for inhibition of the αvβ3 cell surface receptor. Most preferably the present invention provides a method for inhibiting bone resorption, treating osteoporosis, inhibiting humoral hypercalcemia of malignancy, treating Paget's disease, inhibiting tumor metastasis, inhibiting neoplasia (solid tumor growth), inhibiting angiogenesis including tumor angiogenesis, treating diabetic retinopathy and macular degeneration, inhibiting arthritis, psoriasis and periodontal disease, and inhibiting smooth muscle cell migration including restenosis.
Based upon standard laboratory experimental techniques and procedures well known and appreciated by those skilled in the art, as well as comparisons with compounds of known usefulness, the compounds described above can be used in the treatment of patients suffering from the above pathological conditions. One skilled in the art will recognize that selection of the most appropriate compound of the invention is within the ability of one with ordinary skill in the art and will depend on a variety of factors including assessment of results obtained in standard assay and animal models.
Treatment of a patient afflicted with one of the pathological conditions comprises administering to such a patient an amount of compound described above which is therapeutically effective in controlling the condition or in prolonging the survivability of the patient beyond that expected in the absence of such treatment. As used herein, the term "inhibition" of the condition refers to slowing, interrupting, arresting or stopping the condition and does not necessarily indicate a total elimination
15 of the condition. It is believed that prolonging the survivability of a patient, beyond being a significant advantageous effect in and of itself, also indicates that the condition is beneficially controlled to some extent.
As stated previously, the compounds of the invention can be used in a variety of biological, prophylactic or therapeutic areas. It is contemplated that these compounds are useful in prevention or treatment of any disease state or condition wherein the αvβ3 integrin plays a role.
The dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 1000 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions, and more preferably from about 0.01 mg to about 100 mg per kg of body weight per day.
The active ingredient administered by injection is formulated as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose would typically be about 0.01 to 10 mg kg body weight injected per day in multiple doses depending on the factors listed above.
For administration to a mammal in need of such treatment, the compounds in a therapeutically effective amount are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, gelatin, acacia, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated for convenient administration. Alternatively, the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium
16 chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
The pharmaceutical compositions useful in the present invention may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional pharmaceutical adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.
The general synthetic sequences for preparing the compounds useful in the present invention are outlined in Schemes Mil. Both an explanation of, and the actual procedures for, the various aspects of the present invention are described where appropriate. The following Schemes and Examples are intended to be merely illustrative of the present invention, and not limiting thereof in either scope or spirit. Those with skill in the art will readily understand that known variations of the conditions and processes described in the Schemes and Examples can be used to synthesize the compounds of the present invention.
Unless otherwise indicated all starting materials and equipment employed were commercially available.
17 SCHEME I
CO2H HCI, H2θ
1. NH NH^α
Figure imgf000020_0003
Δ
Figure imgf000020_0001
Δ
Figure imgf000020_0005
2. HO/H
Δ
Mel
CO2H
A NH
Figure imgf000020_0004
NH2 NH2
Figure imgf000020_0002
N SMe
^ -CCH HCI 1. DMA HI
Δ *\y ^N 7
HO 2. dilute HCI
Scheme I illustrates methodology useful for preparing the tetrahydropyrimidinobenzoic acid portion of the present invention which can be coupled to a gly-β-amino acid ester. Briefly, in Scheme I, 3,5- dihydroxybenzoic acid is converted to 3-amino-5-hydroxy-benzoic acid using the procedure described in Austr. J. Chem.. 34 (6), 1319-24 (1981 ). The product is reacted with ammonium thiocyanate in hot dilute hydrochloric acid to give 3-thiourea-5-hydroxybenzoic acid after normal work-up. This thiourea intermediate is converted to the S-methyl derivative by reaction with methyl iodide in ethanol at reflux. 1 ,3-diamino- 2-hydroxypropane is reacted with this resulting intermediate in hot DMA. Upon cooling precipitate forms and the zwitterionic product is isolated by filtration. The HCI salt may be obtained by lyophilizing from dilute hydrochloric acid. Alternatively, the product may be isolated from the original reaction mixture by removing volatiles and concentrating. The resulting product is taken up in water and pH adjusted to about 5-7 where zwitterionic product precipitates and is isolated by filtration. The HCI salt may be obtained as previously stated or by simply dissolving in dilute hydrochloric acid and concentrating to a solid and drying.
19 SCHEME IA
-NH2
•A— < *CS2 HO-( =S -→- HO- -S e
EtOHI fi V-NH \- H NH2 Δ
BOCjO CHJOJ, DMA, Et3N
HO
o>=0
CO2H
1. DMA
Δ λ-
1. NH NH^α 2. HO 'OH Δ
Figure imgf000022_0001
NH2
Figure imgf000022_0002
2. HO/HzO
Δ
^r-NH
Figure imgf000022_0003
r )~\ V- cozH -Hci
HO
20 Scheme IA illustrates methodology useful for preparing the tetrahydropyrimidinobenzoic acid portion of the present invention which can be coupled to a gly-β-amino acid ester. Briefly, in Scheme IA 1 ,3- diamino-2-hydroxypropane is reacted with carbon disulfide in an appropriate solvent such as ethanol - water, refluxed, cooled, hydrochloric acid added, refluxed again, cooled and the product, 5- hydroxytetrahydropyrimidine-2-thione harvested by filtration and dried. This cyclic thiourea intermediate is converted to the S-methyl derivative by reaction of thione and methyl iodide in ethanol at reflux. The desired 2- methylthioether-5-hydroxypyhmidine hydroiodide is readily isolated by removing volatiles at reduced pressure. Thus, 2-methylthioether-5- hydroxypyrimidine hydroiodide in methylene chloride : DMA (about 10:1 ) and an equivalent of triethylamnine are cooled to about ice-bath temperature and an equivalent of di-tert-butyl dicarbonate (BOC anhydride) added. Conventional work-up gives the BOC-2- methylthioether-5-hydroxypyrimidine as an oil.
3,5-dihydroxybenzoic acid is converted to 3-amino-5-hydroxy- benzoic acid using the procedure of Aust. J. Chem., 34 (6), 1319-24 (1981 ). The final desired product, 3-hydroxy-5-[(5-hydroxy-1 ,4,5,6- tetrahydro-2-pyrimidinyl)amino]benzoic acid hydrochloride salt, is prepared by reacting BOC-2-methylthioether-5-hydroxypyrimidine and 3-amino-5- hydroxy-benzoic acid in hot DMA. Upon cooling, a precipitate forms and zwitterionic product isolated by filtration. The HCI salt can be obtained by lyophilizing from dilute hydrochloric acid, for example.
21 SCHEME II
0_^ Jή
Ac20/Et3N X TMS2NLi/THF γ^ ^y
Figure imgf000024_0001
,, or -X-Succinifnibe or other source of C EtOH, HCI
CO2E. M
NH
OH
HCI
Figure imgf000024_0002
/ ° v NMM
Figure imgf000024_0003
H Cθ!E' COzEt
lΕtOH l ^A,, H
HCI HC XΎ* ,OH dioxane
Yaπd X are halo groups
22 Scheme π illustrates methodology useful for preparing the ethyl N- gly-amino-3-(3,5-dihalo-2-hydroxy) phenyl propionate portion of the present invention which can be coupled to the tetrahydropyrimidinobenzoic acid moiety. Briefly, 3,5-halo substituted salicylaldehydes may be prepared by direct halogenation as, for example, would be the case where 5-bromosalicylaldehyde is slurried in acetic acid and an equivalent or more of chlorine is added to yield 3-chloro-5-bromo-2-hydroxybenzaldehyde. Some product precipitates and can be recovered by filtration. The remainder may be recovered by diluting the filtrate with water and isolating the precipitate. Combining the solids and drying gives 3-chloro-5-bromo-2- hydroxybenzaldehyde. 3-iodo-5-chlorosalicylaldehyde may be prepared by reacting 5-chlorosalicylaldehyde with N-iodosuccinimide in DMF and subjecting the reaction mixture to usual work-up conditions. 3-iodo-5- bromosalicylaldehyde may be prepared by reacting 5- bromosalicylaldehyde in acetonitrile with potassium iodide and chloramine T. Work-up gives a material that when treated with hexanes gives the desired 3-iodo-5-chlorosalicylaldehyde.
Coumarins are readily prepared from salicylaldehydes using a modified Perkin reaction (e.g., Vogel's Textbook of Practical Organic Chemistry, 5th Ed., 1989, p. 1040, ) . The halo-substituted coumarins are converted to 3-aminohydrocoumarins (see J.G. Rico. Tett. Let.. 1994. 35, 6599-6602) which are readily opened in acidic alcohol to give 3-amino-3- (3,5-halo-2-hydroxy)phenyl propanoic acid esters.
3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters are converted to N-gly-3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters by reaction of Boc-N-gly-N-hydroxysuccinimide to give Boc-N-gly- 3- amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters that are converted to HX salts of N-gly- 3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters (wherein X is a halo group) for example, by removal of the BOC-protecting group using HCI in ethanol.
The amino acid compounds used in preparing the compounds of the present invention can be prepared according to the procedures set forth
23 herein and below and according to the methodology described and claimed in co-pending USSN Attorney Docket 3076, filed simultaneously herewith and hereby incorporated by reference.
24 SCHEME in
-NH
HO-
-N X NH
\ . 1. IBCF, NMM, DMA, >rft
ΉCI = H ?0jB
HO 2. NVM, HJN ^Y p
'HCI
-OH χΛ ,
^- H HO- - ^-
Cθ2Et
Figure imgf000027_0001
'HX
,OH
1. LiOH,H2θ
Figure imgf000027_0002
Y and X are halo groups
25 Scheme πi is illustrative of methodology useful for preparing various compounds of the present invention. 3-Hydroxy-5-[(1 ,4,5,6- tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoic acid is activated to coupling using known methods. Thus, after dissolving in a suitable solvent such as DMA an equivalent of NMM is added. The reaction mixture is cooled to ice-bath temperatures and IBCF added. To the mixed anhydride intermediate is added the gly-β-amino acid ester and NMM. Upon completion of the reaction the product is purified by prep hplc and the ester hydrolyzed to the acid by treating with a base, such as LiOH in a suitable solvent (dioxane/water or acetonitrile/water). Alternatively, a suitable acid, such as TFA can be used. The product is isolated by prep hplc or by isolating the zwitterion at pH 5-7 and converting to the desired salt by standard procedures.
26 EXAMPLE A
Preparation of
XX HQ
Step l
Preparation of
Figure imgf000029_0001
To a 2L round bottom flask fitted with a mechanical stirrer and condenser was added 3, 5-dichlorosalicylaldehyde (200 g, 1.05 mol, 1 equiv.), acetic anhydride (356 g , 3.49 mol) and triethylamine (95.0 g , 0.94 mol, 0.90 equiv.). The reaction solution was heated at reflux overnight. The dark brown reaction mixture was cooled to 50°C and water (1 L) added with stirring. After one hour the mixture was filtered and the filtrate combined with EtOH (1 L). This mixture was heated to 45°C for one hour, cooled to room temperature, filtered and the solid (fraction A) washed with EtOH (0.5 L). The combined EtOH solutions were concentrated by rotary evaporation to an oil (fraction B). The solid from fraction A was dissolved in methylene chloride (1.5 L) and the resulting solution passed through a pad of silica gel (1300 mL volume). The resulting dark brown solution was concentrated to an oil that was triturated with hexanes (1.3 L) to give a solid that was isolated by filtration and washed (hexanes) to give substantially pure 6,8-dichlorocoumarin (163 g). A further 31 g of product was obtained by treating the oil, fraction B, in a similar fashion; the oil was
27 dissolved in methylene chloride (0.5 L) passed through a silica pad (0.5 L volume) and triturated with hexanes. The total isolated yield was 194 g or 86% yield of the brown solid.
MS and NMR were consistent with the desired structure.
Step 2
Preparation of
H2N-[^C02Et ^ 0 * HCI
To a 3-neck 2L round bottom flask fitted with a mechanical stirrer was added 6,8-dichlorocoumarin (160 g, 0.74 mol) (prepared in Step 1 ) and dry THF (375 mL, Aldrich Sure Seal). The resulting mixture was cooled to - 40°C (dry ice/acetone bath) and lithium bis(trimethylsilyl)amide (0.80 mol , 800 mL of 1M in THF) added while maintaining temperature below -40 C. After the completion of the addition the cooling bath was removed . After 0.5 hour the mixture had warmed to -5°C. The reaction was quenched by addition of a solution of HCI (0.5 L of 4M in dioxane) in EtOH (1.25 L). The temperature was maintained below 0°C overnight. The reaction mixture was concentrated to about one-half its original volume and partitioned between EtOAc (3 L) and water (2L). The organic layer was washed with aqueous HCI (3 x 1 L 0.5 N HCI). The pH of the combined aqueous layers was adjusted to about 7 by addition of 10% aqueous NaOH and extracted with methylene chloride (3 x 2L). The combined organic layers were dried (MgSO4), filtered, and 4M HCI in dioxane (210 mL) added with stirring. Upon completion of precipitation the solid was removed by filtration. The filtrate was concentrated to a small volume and methyl t-butyl ether added. The solid obtained was combined with the initially formed solid and the combined product was washed with
28 methyl t-butyl ether, isolated by filtration and dried (vacuum oven over a weekend) to obtain the desired product (172 g, 74% yield).
MS and NMR were consistent with the desired structure.
Step 3 Preparation of
H
A πrV OQzEt o ,OH
cr XI
To a flame-dried round bottom flask (0.5 L) equipped with magnetic stir bar was added N-t-Boc-glycine N-hydroxysuccinimide ester (Sigma, 15.0 g, 0.055 mol), dry DMF (Aldrich Sure Seal, 200 mL) and the product from Step 2 (21.67 g, 0.055 mol) under an inert atmosphere (Ar). The reaction mixture was cooled to approximately 0°C (salt-ice bath) and N- methylmorpholine (5.58 g, 0.056 mole) and a catalytic amount of DMAP added and the reaction allowed to proceed overnight. The reaction mixture was concentrated to a slush, and partitioned between EtOAc (0.4L) and aqueous base (2 x 0.2 L, aqueous saturated NaHCOs). The organic layer was washed consecutively with aqueous citric acid (2 x 0.2 L, 10% w/v), again with aqueous sodium bicarbonate (2 x 0.2 L), brine and dried (Na2S04). Volatiles were removed under vacuum at 55°C to give an oil (22.5 g, 92% yield) that solidified on standing.
MS and NMR were consistent with the desired structure. Step 4
Preparation of
H H N^γN ^CO2Et
HCI
cr ^ i
29 The product obtained in Step 3 was de-protected to give the amine hydrochloride salt using the following procedure. To the product from Step 3 (14.0 g, 0.032 mole) in a flame-dried round bottom flask (0.1 L) with stir bar was added dry dioxane (40 mL). To this was added 4.0 N HCI in dioxane (2 equiv., 6.32 mL) at 0°C and the reaction allowed to proceed until gas evolution ceased and the reaction was complete. Volatiles were removed under vacuum and the residue triturated with diethyl ether (50 mL). Solids were collected by filtration and washed with ether and dried to give the desired product (12.5 g). MS and NMR were consistent with the desired structure.
30 EXAMPLE B
Preparation of
H H /NSsj N ^CO2Et
HCI a °^rτ0 B,H
Figure imgf000033_0003
Steo l
Preparation of
Figure imgf000033_0001
To a suspension of 3-bromo-5-chlorosalicylaldehyde (175.0 g, 743.2 mmol) in acetic anhydride (280.5 mL, 3.0 mol) was added triethylamine (103.6 mL, 743.2 mmol). The reaction solution was heated at reflux for 4.5 hours. The solution was cooled and concentrated in vacuo. To the brown residue was added absolute ethanol (730 mL). The mixture was stored at OX for 14 hours. The brown solid was collected by filtration and washed with cold ethanol. The solid was dried in vacuo to give the desired product (123.0 g, 64% yield). 1H NMR was consistent with the proposed structure.
Step 2 Preparation of
Figure imgf000033_0002
31 To a suspension of the coumarin (40.0 g, 154.1 mmol) in THF (400 mL) at -76X was added, dropwise with stirring, lithium bis(trimethylsilyl)- amide (154.1 mL of a 1M solution in THF). The addition was completed in 10 minutes. The reaction mixture was then stirred for 5 minutes, warmed to -20X and stirred for 15 minutes. To this solution was added acetic acid (9.25 g, 154.1 mmol) in THF (28 mL) over 5 minutes. The mixture was warmed to room temperature and volatiles were removed in vacuo. The residue was dissolved in ether (850 mL), washed with saturated aqueous NaHC03 (2 x 100 mL), brine (2 x 40 mL) and dried (MgSO4). The ether solution was concentrated to about 160 mL and cooled to 0 X. To this suspension was added 4M HCI in dioxane (56.3 mL, 225 mmol) and the mixture was stirred at OX for 30 minutes. The suspension was filtered and the filter cake washed with ether. The solid was dried in vacuo to give the desired product as the HCI salt, dioxane solvate, (45.0 g). 1H NMR was consistent with the proposed structure.
Step 3 Preparation of
HCI
Figure imgf000034_0001
To a suspension of the lactone (142.2 g, 354.5 mmol) in absolute ethanol (533 mL) was added 4M HCI in dioxane (157.8 mL, 631.1 mmol) over 10 minutes. The reaction mixture was stirred at room temperature for 2.5 hours. Volatiles were removed in vacuo. The residue was dissolved in ethyl acetate (450 mL) and the solution kept at OX for 15 hours. The tan precipitate was collected by filtration and washed with cold ethyl acetate. The solid was dried in vacuo to give the desired product as the hydrochloride salt (100.4 g, 79% yield). 1H NMR was consistent with the proposed structure.
32 Step 4 Preparation of
Figure imgf000035_0001
To a flame-dried round bottom flask (0.1 L) equipped with magnetic stir bar was added N-t-Boc-glycine N-hydroxysuccinimide ester (Sigma, 2.72 g, 0.010 mol), dry THF (Aldrich Sure Seal, 50 mL) and the product from Step 3 (3.10 g, 0.01 mole, vacuum desiccated overnight over P205) under an inert atmosphere (Ar). The reaction mixture was cooled to approximately OX (salt-ice bath) and triethylamine (1.01 g, 0.010 mole) was added. The reaction was allowed to proceed overnight. The reaction mixture was concentrated to a semi-solid and worked up in a fashion similar to Example A, Step 3. Volatiles were removed from the organic layer under vacuum at 55X to give an oil (4 g, 83% yield) that solidified on standing.
MS and NMR were consistent with the desired structure.
Step 5 Preparation of
O
Figure imgf000035_0002
HCI C ^"^Br
The product obtained in Step 4 was de-protected to give the amine hydrochloride salt using the following procedure. To the product from Step 4 (4.0 g, 0.0084 mole) in a flame-dried round bottom flask (0.1 L) with stir bar was added dry dioxane (20 mL). To this was added 4.0 N HCI in dioxane (20 mL) and the reaction allowed to proceed until gas evolution
33 ceased and the reaction was complete (about one hour). Volatiles were removed under vacuum and the residue triturated with diethyl ether (50 mL). Solids were collected by filtration and washed with ether and dried to give a light brown solid (2.7 g, 78% yield). MS and NMR were consistent with the desired structure.
34 EXAMPLE C
Preparation of
H
H2N/Sγ ^^COzEt
X HCI
Br' Br
Step l
Figure imgf000037_0001
To a suspension of 3,5-dibromosalicylaldehyde (100 g, 357 mmol) in acetic anhydride (164.8 mL, 1.8 mol) was added triethylamine (45 mL, 375 mmol). The reaction solution was heated overnight at reflux under argon. The solution was cooled to room temperature and a solid mass formed. The dark brown reaction mixture was washed with hot hexanes (3 x 300 mL) and aqueous saturated sodium bicarbonate. The resulting solid was dissolved in EtOAc (2L) and washed with water. The organic layer was dried (sodium sulfate) and concentrated to give a brown solid that was collected by filtration. The solid was dried in vacuo to give substantially pure 6,8-dibromocoumarin (94.2 g, 87% yield).
MS and 1H NMR were consistent with the desired structure.
35 Step 2
ΓΪ° ' HC"V
To 6,8-dibromocoumarin (20.0 g, 0.066 mol) (prepared in Step 1) in 5 THF (100 mL) at -78X was added dropwise with stirring lithium bis(trimethylsilyl)amide (66 mL of a 1M solution in THF). The addition was completed in 10 minutes. The reaction mixture was then stirred for 5 minutes, warmed to OX and stirred for 15 minutes. To this solution was added acetic acid (3.95 g) over one minute. The mixture was warmed to 10 room temperature and volatiles were removed in vacuo. The residue was dissolved in hexanes (500 mL), washed with saturated aqueous NaHCO3 (2 x 100 mL) and dried (Na2SO4). The organic solution was concentrated to give an oil that was immediately taken up in diethyl ether (400 mL) and 4M HCI in dioxane (30 mL) was added with stirring at OX for 30 minutes. 15 Excess HCI was removed in vacuo, the suspension filtered and the filter cake washed with ether. The solid was dried in vacuo to give the desired product as the HCI salt, dioxane solvate (19.9 g).
MS and H NMR were consistent with the desired structure.
) Step 3
H N
2 V^ O2Et
HCI
Br X CA
The lactone prepared in Step 2 above (15 g) was dissolved in absolute ethanol (400 mL) and anhydrous HCI gas was passed through for 25 one minute. The reaction mixture was stirred at room temperature for 2.5 hours. RPHPLC showed complete reaction. The volatiles were removed in vacuo to give a dark residue. The residue was triturated with diethyl
36 ether (500 mL) and the mixture stirred overnight. The tan precipitate was collected by filtration and washed with diethyl ether. The solid was dried in vacuo to give the desired product as the hydrochloride salt (15.2 g). MS and 1H NMR were consistent with the desired structure.
Step 4
I °
CO2Et OH rY'
Br ^^\ Br
To a flame-dried round bottom flask (0.2 L) equipped with magnetic stir bar was added N-t-Boc-glycine N-hydroxysuccinimide ester (Sigma, 8.1 g, 0.030 mol), dry DMF (Aldrich Sure Seal, 50 mL) and the product of Step 3 (12 g, 0.03 mole, vacuum desiccated overnight over P2O5) under an inert atmosphere (Ar). The reaction mixture was cooled to approximately OX (salt-ice bath) and N-methyl morpholine (3.03 g, 0.030 mole) and catalytic DMAP added. The reaction was allowed to proceed overnight warming to room temperature. The reaction mixture was concentrated to a semi-solid and worked up in a fashion similar to Example A, Step 3. Volatiles were removed from the organic layer under vacuum at 55X to give an oil (15.7 g, 93% yield) that solidified on standing. . MS and NMR were consistent with the desired structure.
37 Step 5
H
H2N^
HCI
Br
Figure imgf000040_0001
The product obtained in Step 4 was deprotected to give the amine hydrochloride salt using the following procedure. To the product from Step 4 (13.0 g, 0.0084 mole) in a flame-dried round bottom flask (0.1 L) with stir bar was added dry dioxane (40 mL). To this was added 4.0 N HCI in dioxane (30 mL) and the reaction allowed to proceed until gas evolution ceased and the reaction was complete (about one hour). The volatiles were removed under vacuum and the residue triturated with diethyl ether (50 mL). Solids were collected by filtration and washed with ether and dried to give a solid (10.6 g, 93% yield).
MS and NMR were consistent with the desired structure.
38 EXAMPLE D
Preparation of
H2N^ N ^C02Et
• HCI
Step l
Preparation of 3-chloro-5-bromosalicylaldehyde
Figure imgf000041_0001
To a 5L round bottom flask fitted with a mechanical stirrer and gas addition tube was added 5-bromosalicylaldehyde (495 g, 2.46 mol) and acetic acid at ambient temperature to form a slurry. To this mixture was added chlorine gas at a moderate rate until a slight molar excess of chlorine (183 g, 1.05 mol) had dissolved. After the addition was stopped the reaction allowed to proceed overnight. The solid formed was recovered by filtration and the filtrate diluted into water (2.5L). The mixture was stirred vigorously for 20 minutes, the product collected by filtration and washed with water. The combined solids were vacuum dried to give the desired 3-chloro-5-bromosaiicylaldehyde (475 g, 82% yield).
MS and 1H NMR were consistent with the desired structure.
Step 2
Preparation of 6-bromo-8-chlόrocoumarin
Figure imgf000041_0002
39 To a 5L round bottom flask fitted with a mechanical stirrer and condenser was placed 3-chloro-5-bromosalicylaldehyde (554.1 g, 2.35 mol, 1 equiv.), acetic anhydride (1203g , 11.8 mol, 5 equiv.) and triethylamine (237.4 g , 2.35 mol, 1 equiv.). The reaction solution was heated at reflux (131-141 X) overnight. The dark brown reaction mixture was cooled to 50X and ice (2 L) added (ice-bath cooling) with stirring. After one hour the mixture was filtered and the filtrate combined with EtOH (1 L). To this mixture was added EtOH (300 mL) and the reaction mixture stirred for one hour. The precipitate that formed was collected by filtration and washed with water : EtOH (3 x 1.3 L), vacuum and dried then dried on a fluid-bed drier. The total isolated yield is 563 g or 92%.
MS and 1H NMR were consistent with the desired structure.
Step 3
Preparation of 3-amino-3- (2-hydroxy-3-chloro-5-bromo)phenyl propanoic acid ethyl ester
H2N,
XO2Et
A^y 0H • Hci
B .rr^" ^^N ^Cl To a 3-neck 5L round bottom flask fitted with a mechanical stirrer was added 6-bromo-8-chlorocoumarin (300 g, 1.16 mol) (prepared in Step 2) and dry THF (900 mL, Aldrich Sure Seal). The resulting mixture was cooled to less than -45X (dry ice/acetone bath) and lithium bis (trimethylsilyl)amide (0.80 mol , 800 mL of 1 M in THF and 0.6 L in hexanes, 1.2 equivalents) added while maintaining temperature below -45X for 0.5 hour. In a separate 5L flask EtOH (2.5 L) and HCI (4 N HCI in dioxane, 1 L) were combined at -15X. The coumarin reaction was quenched by addition of the cooled HCI / EtOH solution. After 0.5 hour the resulting reaction mixture temperature was -8.3X. The reaction mixture was kept at OX overnight, concentrated to about 2.5 L and partitioned
40 between EtOAc (3 L) and water (4 L). The organic layer was washed with aqueous HCI (4 x 1.2 L, 0.5 N HCI). The pH of the combined aqueous layers was adjusted to about 8 by addition of 10% aqueous NaOH and extracted with methylene chloride (1x7 L and 3 x 2L). The combined organic layers were dried (MgS04, 900 g), filtered, and 4M HCI in dioxane (400 mL) added with stirring. Upon completion of precipitation the solid was removed by filtration. The mixture was concentrated to 2.5 L, hexanes added (2.5 L) and the precipitate isolated by filtration. The filter cake was washed with methylene chloride/hexanes (1 : 2), suction dried and vacuum oven dried at 40X to obtain the desired product (251 g, 60% yield). MS and 1H NMR were consistent with the desired structure.
Step 5
Preparation of
^o^N-^γNγ^co2Et
H B °r xOH
The above compound was prepared using essentially the same procedure and relative quantities as specified for its isomer in Example B, Step 4. MS and 1H NMR were consistent with the desired structure.
Step 6
Preparation of
H H2N'^Nγ^CO2Et
A : -
41 This compound was prepared using essentially the same procedure and relative quantities as specified for its isomer in Example B, Step 5. MS and H NMR were consistent with the desired structure.
42 EXAMPLE E
Preparation of
H
H2N'^N[ N r/^C02Et
HCI
Step l
Preparation of 3-iodo-5-chlorosalicylaldehyde.
Figure imgf000045_0001
N-lodosuccinimide (144.0 g, 0.641 mole) was added to a solution of 5-chlorosalicylaldehyde (100 g, 0.638 mole) in dimethylformamide (400 mL). The reaction mixture was stirred for 2 days at room temperature. Additional N-iodosuccinimide (20.0 g) was added and the stirring was continued for an additional 2 days. The reaction mixture was diluted with ethyl acetate (1 L), washed with hydrochloric acid (300 mL, 0.1 N), water (300 mL), sodium thiosulfate (5%, 300 mL), brine (300 mL), dried (MgSO4) and was concentrated to dryness to afford the desired aldehyde (162 g, 90% yield) as a pale yellow solid.
MS and NMR were consistent with the desired structure.
Step 2
Preparation of 6-chloro-8-iodocoumarin
Figure imgf000045_0002
43 A mixture of 3-iodo-5-chlorosalicylaldehyde (100 g, 0.354 mole), acetic anhydride (300 mL) and triethylamine (54 mL) was heated at reflux for 18 hours. Upon cooling, the desired coumarin precipitated as a dark brown crystalline material. This was filtered, washed with hexane/ethyl 5 acetate (4:1 , 200 mL), and was air dried. Yield: 60 g (55%).
MS and 1H NMR were consistent with the desired structure.
Step 3
Preparation of (R,S) -4-amino-3,4-dihydro-6-chloro-8-iodocoumarin 0 hydrochloride.
H2N. /^O • HCI
Figure imgf000046_0001
cr
Lithium hexamethyldisilazane (21.62 mL, 1M, 21.62 mmol) was added to a solution of 6-chloro-8-iodocoumarin (6.63 g, 21.62 mmol) in tetrahydrofuran (100 mL) at -78X. The reaction mixture was stirred at this 5 temperature for 30 minutes, then at OX for 1 hour. Acetic acid (1.3 g, 21.62 mmol) was added to the reaction mixture. The reaction mixture was poured into ethyl acetate (300 mL) and saturated sodium carbonate (200 mL) solution. The organic layer was separated, washed with brine (200 mL), dried (MgS04), and was concentrated to afford a residue. The υ residue was added to anhydrous ether (200 mL) followed by dioxane/HCI (4N, 30 mL) at OX. The reaction mixture was stirred for 1 hour at room temperature, filtered, and was dried in vacuo to afford the desired product (4.6 g, 59% yield) as a powder. (RPHPLC: Rf 6.8 minutes; Gradient 10% acetonitrile -90% acetonitrile over 15 minutes then to 100% acetonitrile 5 over the next 6 minutes. Both water and acetonitrile contain 0.1 % TFA. Vydac C18 protein peptide column, 2 mlJ minutes flow rate, monitored at 254 nm).
MS and 1H NMR were consistent with the desired structure.
44 Step 4
Preparation of (R, S)-Ethyl 3-amino-3-(5-chloro-2-hydroxy-3-iodo)phenyl propionate hydrochloride.
H2N.
Cθ2Et
HCI
Figure imgf000047_0001
Hydrogen chloride gas was bubbled into a solution of 4-amino-3,4- dihydro-6-chloro-8-iodocoumarin hydrochloride (22.0 g, 61.09 mmol) in ethanol (250 mL) keeping the reaction mixture at 0-1 OX till saturation. After 6 hours at reflux, most of the solvent was removed by distillation. The cooled residue was added to anhydrous ether and was stirred for 2 hours. The initial gum turned into a crystalline material. The crystalline product was filtered and was dried to afford the desired product (20 g, 81% yield) as a off-white crystalline powder. (Rf 7.52 minutes, conditions as Step 3).
MS and 1H NMR were consistent with the desired structure.
Step 5
Preparation of (R.S)-ethyl 3-(N-BOC-gly)-amino-3-(5-chloro-2-hydroxy-3- iodo)phenyl propionate. o H
>^A iTY O Nr^^ ^OH*
A mixture of BOC-gly (2.16 g, 12.31 mmol), HOBT (1.67 g, 12.31 yield), EDCI (2.36 g, 12.31 mmol) and DMF (50 mL) was stirred at OX for 1 hour. Ethyl 3-amino-3-(5-chloro-2-hydroxy-3-iodo)propionate hydrochloride (5.0 g, 12.31 mmol) was added to the reaction mixture followed by triethylamine (3.5 mL). The reaction mixture was stirred for 18 hours at room temperature. DMF was removed in vacuo and the residue
45 was partitioned between ethyl acetate (300 mL) and sodium bicarbonate (200 mL). The organic layer was washed with hydrochloric acid (1 N, 100 mL), brine (200 mL), dried (MgSO4) and was concentrated to afford the desired product as a solid (6 g, 93% yield). MS and 1H NMR were consistent with the desired structure.
Step 6
Preparation of (R.S)-ethyl 3-(N-gly)-amino-3-(5-chloro-2-hydroxy-3- iodo)phenyl propionate hydrochloride.
H H2N'"'V ' ^ C02Et
OH
HCI cr
Dioxane/HCI (4N, 20 mL) was added to ethyl 3-(N~BOC-gly)-amino- 3-(5-chloro-2-hydroxy-3-iodo)propionate (6.0 g, 11.39 mmol) at OX and was stirred at room temperature for 3 hours. The reaction mixture was concentrated, and concentrated once more after addition of toluene (100 mL). The residue obtained was suspended in ether and was filtered and dried to afford the desired product as a crystalline powder (5.0 g, 95% yield). (RPHPLC : Rf 8.3 minutes, conditions as in Step 3).
MS and 1H NMR were consistent with the desired structure.
46 EXAMPLE F
Preparation of
H2N'"NγNvr/^co2Et
IXC • HCI
Step l Preparation of 3-iodo-5-bromosalicylaldehyde
To a solution of 5-bromosalicylaldehyde (20.0 g, 0.1 mole) and potassium iodide (17 g , 0.1 mole) in acetonitrile (150 mL) and water (50 mL) in a 500 mL round bottom flask with magnetic stirrer was added chloramine T (23 g, 0.1 mole). The mixture was allowed to react for one hour. The reaction mixture was partitioned between hydrochloric acid (10%, 200 mL) and ethyl acetate. The organic layer was dried (Na2SO_ι), filtered and concentrated in vacuo. To the residue was added hexanes and the reaction mixture heated to 50X for 15 minutes. The undissolved material was removed by filtration. The filtrate was concentrated in vacuo to leave canary yellow 3-iodo-5-bromosalicylaldehyde (26 g).
MS and 1H NMR were consistent with the desired structure.
Step 2
,OH
• HCI
Br'
The above compound was prepared using essentially the same procedure of Example E, Steps 2-6 where in Step 2, an equivalent amount of product from Step 1 , 3-iodo-5-bromo-salicylaldehyde, was substituted for 3-iodo-5-chlorosalicylaldehyde.
MS and 1H NMR were consistent with the desired structure.
47 EXAMPLE H Preparation of
H
N • HCI
HO v H- OH
OH
Stee l
Ethanol (375 mL) and deionized water (375 mL) were added to a 2L 3-neck round bottom flask fitted with a mechanical stirrer, Claisen adapter, addition funnel, reflux condenser and thermocouple. 1 ,3- diamino-2- hydroxypropane (125.04 g, 1.39 mol) (Aldrich) was added to the reaction flask and stirred to dissolve. Carbon disulfide (84 mL , 1.39 mol) was added in a drop-wise fashion via addition funnel at 25-33X over a 35 minute period to afford a milky-white mixture. The temperature was maintained with an ice bath. The reaction mixture was refluxed at 73.4X for two hours to afford a yellow solution. The reaction mixture was cooled with an ice bath to 25X and concentrated HCI (84 mL) was added in drop- wise fashion while maintaining the temperature at 25-26X. The reaction mixture was refluxed for 21 hours at 78.4X. The reaction solution was cooled to 2X and product collected via vacuum filtration. The white solid was washed 3 times with ice bath chilled ethanol : water (1 :1 ) (50 mL) and dried in vacuo at 40X to afford 5-hydroxytetrahydropyrimidine-2-thione (63.75 g, 34.7% yield) as a white solid.
MS and NMR were consistent with the desired structure. Step 2
5-Hydroxytetrahydropyrimidine-2-thione (95 g, 0.72 mol) prepared in
Step 1 , absolute ethanol (570 mL), and methyl iodide (45 mL , 0.72 mol) were added to a 2 L round bottom flask fitted with a mechanical strirrer and thermocouple. The reaction mixture was refluxed at 78X for 5 hours and then cooled to room temperature. The reaction mixture was concentrated
48 in vacuo to afford a white solid (194.72 g). The white solid was triturated 3 times with ethyl ether (500 mL ) and dried in vacuo to afford 2- methylthioether-5-hydroxypryrimidine hydroiodide (188.22 g, 95.4% yield) as a white solid. MS and *H NMR were consistent with the desired structure.
Step 3
2-Methyl thioether-5-hydroxypyrimidine hydroiodide (150.81 g, 0.55 mol), methylene chloride (530 mL), dimethylacetamide (53 mL) and triethylamine (76.7 mL, 0.55 mol) were added to a 2L 3-neck round bottom flask fitted with reflux condenser, mechanical stirrer and a static atmosphere of nitrogen. The mixture was cooled with an ice bath and di- tert -butyl dicarbonate (120.12 g, 0.55 mol) was added at 4X. The reaction mixture was heated at 42.5X for 18 hours to afford a light yellow solution. The reaction solution was transferred to a 2L separatory funnel and washed 3 times with DI water (200 mL), dried with MgS04, filtered and concentrated in vacuo to afford Boc-2-methylthioether-5-hydroxypyrimidine (134.6 g, 99.35% yield) as a light yellow viscous oil. MS and H NMR were consistent with the desired structure.
Step 4
Boc-2-methylthioether-5-hydroxypyrimidine (50.3 g, 0.204 mol), 3- amino-5-hydroxybenzoic acid (Aust. J. Chem. (1981 ) 34(6), 1319-24) (25.0 g, 0.1625 mole) and 50 mL anhydrous DMA were heated at 100X with stirring for 2 days. A slurry precipitate resulted. The reaction was cooled to room temperature and the precipitate was filtered, washed with CH3CN, then ethyl ether and dried. This solid was slurried in H2O and acidified with concentrated HCI resulting in a solution. This was frozen and lyophilized to yield the desired product as a white solid (14.4 g). MS and 1H NMR were consistent with the desired structure.
49 EXAMPLE I
Preparation of
Figure imgf000052_0001
(S isomer)
Stee l
Preparation of Reformatsky Reagent
— CO2-t-Bu Br-Zn
A 4-L flask fitted with a condenser, temperature probe and mechanical stirrer was charged with Zn metal (180.0 g, 2.76 mol, -30 - 100 mesh) and THF (1.25 L). While stirring, 1 ,2-dibromoethane (4.74 mL, 0.05 mol) was added via syringe [alternatively, TMS Cl (0.1 equivalent) at room temperature for one hour can be substituted]. After inert gas purge (3 N2/vacuum cycles) the suspension of zinc in THF was heated to reflux (65X) and maintained at this temperature for 1 hour. The mixture was cooled to 50X before charging tert-butyl bromoacetate (488 g, 369 mL, 2.5 mol) via 50 mL syringe and syringe pump (delivery set to 4.1 mlJminutes) over 1.5 hours. Reaction temperature of 50° +/- 5X was maintained throughout the addition. The reaction mixture was allowed to stir at 50X for one hour after the addition was complete. Subsequently, the mixture was allowed to cool to 25X and the precipitated product allowed to settle. The THF mother liquor was decanted into a 2-L round bottom flask using a coarse fritted filter stick and partial vacuum transfer (20 mm Hg). This removed about 65% of the THF from the mixture. 1- Methyl-2-pyrrolidinone (NMP, 800 mL) was added and agitation resumed for 5 minutes. The reaction mixture can be filtered to remove any remaining zinc. Analysis indicated a titer of desired Reformatsky reagent
50 of 1.57 M with a molar yield of 94%. Alternatively, the solid reagent can be isolated by filtration from the original reaction mixture. The cake can be washed with THF until a white solid is obtained and dried under N2 to obtain the desired product as a mono THF solvate that may be stored at - 20X (desiccated) for extended periods. Typical recoveries are 85-90%.
Step 2
2A. Preparation of
Figure imgf000053_0001
Potassium carbonate (powder, oven dried at 100X under vacuum, 8.82 g, 60 mmoles) was added to a solution of 3,5-dichlorosalicylaldehyde (11.46 g, 60 moles) in DMF (40 mL) at room temperature to give a bright yellow slurry. MEMCI (neat, 7.64 g, 61 mmoles) was then added while maintaining the bath temperature at 20X. The mixture was then stirred at 22X for 6 hours and MEMCI (0.3 g, 2.4 mmoles) was added. The mixture was stirred for another 0.5 hour and the reaction mixture poured into cold water (200 mL) to precipitate the product. The slurry was filtered on a pressure filter and the cake was washed with water (2 x 50mL) and was dried under N2/vacuum to afford the product (14.94g, 89%) as a off white solid. 1H NMR (CDCI3, TMS) 3.37 (s, 3H), 3.54 to 3.56 (m, 2H), 3.91 to 3.93 (m, 2H), 5.30 (s, 2H), 7.63 (d, 1 H), 7.73 (d, 1 H), 10.30 (s, 1 H); 13C NMR (CDCI3, TMS) d (ppm):59.03, 70.11 , 99.57, 126.60, 129.57, 130.81 , 132.07, 135.36, 154.66, 188.30. DSC: 48.24X (endo 90.51 J/g);
Microanalytical: calcd for CιιH12CI O4: C: 47.33%; H: 4.33%; Cl: 25.40%; found: C: 47.15%; H:4.26%; Cl: 25.16%.
51 2B. Preparation of
Figure imgf000054_0001
The product from Step 2A (35.0 g, 0.125 mol) was charged in a 1-L 3-neck round bottom flask fitted with a mechanical stirrer and an addition funnel followed by addition of THF (200 mL).The solution was stirred at 22X and (S)-phenylglycinol (17.20 g, 0.125 mol) was then added at once. After 30 minutes at 22X, MgSO4 (20 g) was added. The mixture was stirred for 1 hour at 22X, and filtered on a coarse fritted filter. The filtrate was concentrated under reduced pressure. No further purification was performed and the crude imine was used directly in the coupling reaction, Step 2, C.
2C. Preparation of
OH r-^
Figure imgf000054_0002
NH
Figure imgf000054_0003
A 1-L 3-neck round bottom flask fitted with a mechanical stirrer and an addition funnel was charged with the solid reagent produced in Step 1 (91.3 g, 0.275 mol) and NMP (200 mL) under nitrogen. The solution was then cooled to -10X and stirred at 350 rpm. A solution of imine (prepared in Step 2B) in NMP was prepared under nitrogen and then added over 20
52 minutes to the above reaction mixture while the temperature was maintained at -5X (jacket temperature -1 OX). The mixture was stirred for an additional 1.5 hours at -8X and one hour at -5X after the addition was complete.. After cooling to -10X a mixture of concentrated HCI/saturated solution of NH4CI (8.1 mL/ 200 mL) was added in 10 minutes. MTBE (200 ml) was added and the mixture was stirred 15 minutes at 23X at 200 rpm. Stirring was stopped and the layers separated. The aqueous layer was extracted with MTBE (100 mL). The two organic layers were combined, washed successively with a saturated solution of NH4CI (100 mL), water (100 mL) and brine (100 mL). The solution was dried with MgS04 (30 g), filtered and concentrated to afford an orange oil (66.3 g) (solidifies in standing) containing the desired product as a single diastereoisomer (confirmed by proton and carbon nmr). A sample was purified for analysis by recrystallization from heptane to afford the product as an off-white solid. Proton and carbon NMR and IR spectra were consistent with the desired structure. [α]D 2s = + 8.7° (c = 1.057, MeOH). Microanalytical: calcd for C25H33CI2NO6:
C: 58.77%; H: 6.47%; N: 2.72%; Cl: 13.78% found: C: 58.22%; H: 6.54%; N: 2.70%; Cl: 13.66%.
Step 3 Preparation of
Figure imgf000055_0001
3A. A solution of the crude ester prepared in Step 2 [17.40 g, 0.033 mole (theory)], and EtOH (250 mL) was charged to a 1-L 3-neck jacketed reactor. The solution was cooled to OX and Pb (OAc)4 ( 14.63 g, 0.033 mole) was added at once. After 2 hours a 15% solution of NaOH (30 mL)
53 was added and ethanol was removed under reduced pressure. Another portion of 15% NaOH (100 mL) was added and the mixture extracted with MTBE (2 x 100 mL), washed with H2O (2 x 100 mL) and brine (50 mL), dried with Na2S04l filtered on celite and concentrated under reduced pressure to afford an orange oil (12.46 g). The oil was homogeneous by thin layer chromatography (tic) and was used without further purification.
3B. The oil from 3A was diluted with EtOH (30 mL) and paratoluene sulfonic acid (1.3 equiv., 0.043 mole, 8.18 g) was added. The solution was heated to reflux for 8 hours, cooled to ambient temperature and concentrated under reduced pressure. The residue was treated with THF (20 mL) and heated to reflux to form a solution. The solution was cooled to room temperature and the compound crystallized. Heptane (30 mL) and THF (10 mL) were added to form a fluid slurry which was filtered. The cake was washed with THF/heptane (40 mL, 1/1 ) and vacuum dried for two hours in a pressure filter under nitrogen to afford a white solid (7.40 g). Proton and carbon NMR and IR spectra were consistent with the desired product as substantially a single enantiomer. Microanalytical: calcd for CiβH∑iCI∑NOeS, 0.25 C4H80: C: 48.73%; H: 4.95%; N: 2.99%; Cl: 15.14% found: C: 48.91 %; H: 4.95%; N: 2.90%; Cl:14.95%.
Step 4
Preparation of
0 H
^cA
Figure imgf000056_0001
54 To a 500 mL round bottom flask equipped with a magnetic stir bar and nitrogen bubbler were charged the free base of the product produced in Step 3 (21.7 g , 0.065 mole), N-t-Boc-giycine N-hydroxysuccinimide ester (17.7 g, 0.065 mole) and DMF (200 mL). The reaction mixture was stirred under nitrogen at room temperature for 3.25 hours and a pale orange solution formed. The reaction mixture was poured into ice-cold ethyl acetate (1.2 L). The organic solution was washed with 1M HCI (250 mL) and then with brine (500 mL), dried (MgSO4) and concentrated under vacuum to near dryness to obtain an oil that was subsequently dried at 50X to obtain the product as a colorless oil (28.12 g , 99 %). Seed crystals were prepared from ethyl acetate/hexanes. The product (about 28 g) was dissolved in ethyl acetate (35 mL) and hexanes (125 mL). The solution was seeded with the seed crystals and precipitate formed. The solids were filtered and dried overnight under vacuum at 55X to yield a colorless solid (27.0 g, 95%).
MS and 1H NMR were consistent with the desired structure.
Step 5
Preparation of
H co2Et
3 ^γ0H • HCI
Cl λ Cl
The Boc-protected glycine amide prepared in Step 4 (27.0 g, 0.062 mole) was dried overnight over P2O5 and NaOH pellets. The solid was dissolved in dioxane (40 mL) and the solution cooled to OX. An equivalent volume of 4N HCI/dioxane (0.062 mole) was added and the reaction was run for 2 hours. At this point the conversion was 80% by RPHPLC. The reaction mixture was allowed to warm to room temperature
55 over 4 hours. The reaction mixture was concentrated at 40X to a foam which was triturated with ether (200 mL). The white solid that formed was filtered and dried over P2Osto yield the desired glycine beta-amino acid ethyl ester compound, as an HCI salt (20.4g, 88.5% isolated yield). MS and 1H NMR were consistent with the desired structure.
56 EXAMPLE J
Preparation of H P°2
H2N
HCI
Step l x ■
Preparation of
Figure imgf000059_0001
MEM protected 3-bromo-5-chlorosalicylaldehyde (129.42 g, 0.4 mol), prepared according to the procedure of Example I, Step 2A. An equivalent amount of 3-bromo-5-chlorosalicylaldehyde was substituted for 3,5-dichlorosalicylaldehyde, which was charged in a 2-L 3-neck round bottom flask fitted with a mechanical stirrer, followed by addition of THF (640 ml) and (S)-phenylglycinol (54.86 g, 0.4 mol). After 30 minutes at 22X, MgS04 (80 g) was added. The mixture was stirred for 2 hours at 22X, and filtered on a coarse fritted filter. The filtrate was concentrated under reduced pressure to afford a pale yellow oil (180.0 g) containing the desired imine. No further purification was performed and the crude product was used directly in the coupling reaction, Step 2. Microanalytical: calcd for Cι9H2ιBrCINO_.:
C: 51.54%; H: 4.78%; N: 3.16%; Br: 18.04%; Cl: 8.00% found: C: 50.22%; H: 4.94%; N: 2.93%; Br: 17.15%; Cl:7.56%.
57 Step 2
Preparation of
Figure imgf000060_0001
In a 5-L 3-neck round bottom flask fitted with a mechanical stirrer, the reagent from Example I, Step 1 (332.0 g, 0.8 mol) was taken up in NMP (660 mL) under nitrogen. The solution was then cooled to -10X. A solution of imine from Step 1 in NMP (320 ml) was prepared under nitrogen and then added over 30 minutes to the above reaction mixture while the temperature was maintained at -5X. The mixture was stirred for an additional hour at -8X and at -5X for 2 hours after addition was complete and then cooled to -10X. A mixture of concentrated HCI/saturated solution of NH4CI (30mLJ720 mL) was added over 10 minutes. MTBE (760 ml) was added and the mixture was stirred for 30 minutes at 23X. Stirring was stopped and the layers separated. The aqueous layer was extracted with MTBE (320 ml). The organic layers were combined, washed successively with saturated aqueous NH4CI (320 ml), DI water (320 ml) and brine (320 ml). The solution was dried with MgS04 (60 g), filtered and concentrated to afford a yellow oil (221.0 g) containing the desired product as a single diastereoisomer as determined by proton NMR. DSC: 211.80X (endo. 72.56 J/g), 228.34X (98.23 J/g); Microanalytical: calcd for C25H33BrCINO6:
C: 53.72%; H: 5.95%; N: 2.50%; Br: 14.29%; Cl: 6.33% found: C: 52.1 1 %; H: 6.09%; N: 2.34 %; Br: 12.84%; Cl:6.33%.
58 Step 3 Preparation of
SO3H
Figure imgf000061_0001
Figure imgf000061_0002
A solution of crude ester, prepared in Step 2 (-111 g), in ethanol (1500 mL) was charged under argon atmosphere to a 3-L 3-neck round bottom flask fitted with a mechanical stirrer. The reaction mixture was cooled to OX and lead tetraacetate (88.67 g, 0.2 mol) was added in one portion. The reaction mixture was stirred for 3 hours at OX and then 15% aqueous NaOH (150 mL) was added to the reaction mixture below 5X. Methanol was removed under reduced pressure on rotavap. Another 150 mL of 15% aqueous NaOH was added and the reaction mixture was extracted with ethyl acetate (3 x 300 mL) and washed with DI water (2 x 100 mL) and brine (2 x 100 mL) and dried over anhydrous MgS04 (30 g). It was then filtered over celite and concentrated under reduced pressure to give the desired product (103 g) as a red oil.
Step 4 Preparation of
H C02Et H2N^ γ
HCI
Figure imgf000061_0003
Cl' The above compound was prepared according to the procedure employed for Example I, Step 4 and Step 5 by substituting an equivalent amount of the product from Step 3 in Example I, Step 4. MS and H NMR were consistent with the desired structure.
59 EXAMPLE K Alternate Preparation of the compound of Example J
Step 1 Preparation of
Figure imgf000062_0001
To the product of Example B, Step 3, (50.0 g, 139.2 mmol) and NaHCO3 (33.5 g, 398.3 mmol) was added CH2CI2 (500 mL) and water (335 mL). The mixture was stirred at room temperature for 10 minutes. A solution of benzyl chloroformate (38.0 g, 222.8 mmol) in CH2CI2 (380 mL) was added over 20 minutes with rapid stirring. After 50 minutes, the reaction mixture was poured into a separatory funnel and the organic layer collected. The aqueous phase was washed with CH2CI2 (170 mL). The combined organic layers were dried (MgSO4) and concentrated in vacuo. The resulting gummy solid was triturated with hexane and collected by filtration. The tan solid was dried in vacuo to give the desired racemic product (61.2 g, 96% yield). This material was subjected to reverse phase HPLC using a chiral column to give each pure enantiomer. The column employed was a Whelk-O (R,R), 10 micron particle size using a 90 : 10 heptane : ethanol mobile phase. Optical purity was determined to be > 98% using analytical hplc using similar column and solvent conditions. 1H NMR was consistent with the proposed structure.
Step 2
'CC^Et ,OH
60 To a solution of the compound obtained in Step 1 (48.5 g, 106.2 mmol) in CH2CI2 (450 mL) was added trimethylsilyl iodide (25.5 g, 127.4 mmol) in CH2CI2 (100 mL) via canula. The orange solution was stirred at room temperature for 1 hour. Methanol (20.6 mL, 509.7 mmol) was added dropwise and the solution stirred for 15 minutes. The reaction solution was concentrated in vacuo to give an orange oil. The residue was dissolved in methyl f-butyl ether (500 mL) and extracted with 1N HCI (318 mL) and water (1 x 200mL, 1 x 100 mL). The aqueous extracts were back washed with MTBE (100 mL). To the aqueous solution was added solid NaHCO3(40.1 g, 478 mmol) in small portions. The basified aqueous mixture was extracted with MTBE (1 X 1 L, 2 X 200 mL). The combined organic solution was washed with brine and concentrated in vacuo to give the desired product (23.3 g, 68% yield). 1H NMR was consistent with the proposed structure.
Step 3 Preparation of
Figure imgf000063_0001
To a solution of the product from Step 2 (23.3 g, 72.1 mmol) in DMF (200 mL) was added N-t-Boc-glycine N-hydroxysuccinimide ester (17.9 g, 65.9 mmol). The reaction mixture was stirred at room temperature for 20 hours. The mixture was poured into ethyl acetate (1.2 L) and washed with 1M HCI (2 X 250 mL), saturated aqueous NaHCO3 solution (2 X 250 mL) and brine (2 X 250 mL). The solution was dried (MgSO4) and concentrated to give the desired product (32.0 g, 100 % yield). Anal, calcd for Ci8H24BrCIN2O6: C, 45.06; H, 5.04; N, 5.84.
Found: C, 45.17; H, 5.14; N, 6.12.
1H NMR was consistent with the desired structure.
61 Step 4
H,N ^COjEt
Figure imgf000064_0001
,OH
HCI
To a solution of the product of Step 3 (31.9 g, 66.5 mmol), in absolute ethanol (205 mL) was added an ethanolic HCI solution (111 mL of a 3M solution, 332.4 mmol). The reaction solution was heated at 58X for 30 minutes. The solution was cooled and concentrated in vacuo. The residue was dissolved in ethyl acetate (250 mL) and stirred at OX for 2 hours. A white precipitate was collected by filtration and washed with cold ethyl acetate. The solid was dried in vacuo to give the desired product (23.5 g, 85% yield).
Anal, calcd for Ci3H16BrCIN2O4 + 1.0 HCI: C, 37.53; H, 4.12; N, 6.73.
Found: C, 37.29; H, 4.06; N, 6.68.
1H NMR was consistent with the desired structure.
62 EXAMPLE L
Preparation of
C02Et
HCI
Br-^-^CI
Step l Preparation of
H^O
Figure imgf000065_0001
Potassium carbonate (powder, oven dried at 100X under vacuum, 22.1g, 0.16 moles) was added to a solution of 3-chloro-5- bromosalicylaldehyde (35.0 g, 0.15 moles) in DMF (175 ml) at room temperature to give a bright yellow slurry. MEMCI (neat, 25.0 g, 0.2 moles) was then added while maintaining the bath temperature at 20X. The mixture was then stirred at 22X for 6 hours and was poured into DI water (1200mL) to precipitate the product. The slurry was filtered on a pressure filter and the cake was washed with DI water (2 x 400 mL) and was dried under N2/vacuum to afford the product (46. Og, 95 % yield) as an off white solid. 1H NMR (CDCI3, TMS) 3.35 (s, 3H), 3.54 to 3.56 (m, 2H), 3.91 to 3.93 (m, 2H), 5.30 (s, 2H), 7.77 (d, 1 H), 7.85 (d, 1 H), 10.30 (s, 1 H); 13C NMR (CDCI3, TMS) (ppm):59.05, 70.11 , 71.49, 99.50, 117.93, 129.69, 129.78, 132.37, 138.14, 155.12, 188.22. DSC: 48.24X (endo 90.51 J/g); Microanalytical: calcd for CnHι2BrCIO4:
C: 40.82%; H: 3.74%; Cl: 10.95%; Br: 24.69%; found: C: 40.64%; H:3.48%; Cl: 10.99%; Br 24.67%.
63 Step 2 Preparation of
Figure imgf000066_0001
The product from Step 1 (32.35 g., 0.1 mol) was charged in a 500 ml
3N round bottom flask fitted with a mechanical stirrer, followed by addition of THF (160 ml) and (S)-phenylglycinol (13.71 g, 0.1 mol). After 30 minutes at 22X, MgSO4 (20 g.) was added. The mixture was stirred for 1 hour at 22X and filtered on a coarse fritted filter. The filtrate was concentrated under reduce pressure to afford a pale yellow oil (48.0 g) containing the desired imine. No further purification was performed and the crude product was used directly in the next reaction step. Microanalytical: calcd for C.9H21BrCINO4:
C: 51.54%; H: 4.78%; N: 3.16%; Br: 18.04%; Cl: 8.00% found: C: 51.52%; H: 5.02%; N: 2.82%; Br: 16.31%; Cl:7.61 %.
Step 3 Preparation of
OH r ^
Figure imgf000066_0002
NH
Figure imgf000066_0003
In a 5L 3N round bottom flask fitted with a mechanical stirrer, reagent from Example I, Step 1 , (332 g, 0.8 mol) was taken up in NMP
64 (660 mL) under nitrogen. The solution was then cooled to -1 OX. A solution of imine produced in Step 2, in NMP (320 ml) was prepared under nitrogen and then added over 30 minutes to the above reaction mixture while the temperature was maintained at -5X. The mixture was stirred for an additional hour after the addition was complete and cooled to -10X. A mixture of concentrated HCI/saturated solution of NH4CI (30mL/720 mL) was added over 10 minutes. MTBE (760 ml) was added and the mixture was stirred for 1 hour at 23X. Stirring was stopped and the layers were separated. The aqueous layer was extracted with MTBE (320 ml). The two organic layers were combined, washed successively with a saturated solution of NH4CI (320 ml), DI water (320 ml) and brine (320 ml). The solution was dried with MgSO4 (60 g), filtered and concentrated to afford a yellow oil (228 g) containing the desired product as a single diastereoisomer. DSC: 227.54X (endo. 61.63 J/g); Microanalytical: calcd for C25H33BrCINO6:
C: 53.72%; H: 5.95%; N: 2.50%; Br: 14.29%; Cl: 6.33% found: C: 53.80%; H: 6.45%; N: 2.23%; Br: 12.85%; Cl:6.12%.
Step 4
Preparation of
Figure imgf000067_0001
A solution of crude ester produced in Step 3 (-111 g) in ethanol (1500 mL) was charged under nitrogen atmosphere to a 3L 3N round bottom flask fitted with a mechanical stirrer. The reaction mixture was cooled to OX and lead tetraacetate (88.67 g, 0.2 mol) was added in one portion. The reaction mixture was stirred for 3 hours at OX and then 15%
65 aqueous NaOH (150 mL) was added to the reaction mixture below 5X. The ethanol was removed under reduced pressure on rotavap. Another 600 mL of 15% aqueous NaOH was added and the reaction mixture was extracted with ethyl acetate (2 x 300 mL), MTBE (2 x 200 mL ) and ethyl acetate (2 x 200 mL). The organic layers were combined and washed with DI water (2 x 200 mL) and brine (2 x 100 mL) and dried over anhydrous MgSO4 (30 g). The solution was then filtered over celite and concentrated under reduced pressure to give the product as an orange oil (96 g) that was used in the next step without further purification. DSC: 233.60X (endo. 67.85 J/g);
Microanalytical: calcd for C2 H29BrCIN05:
C: 54.71 %; H: 5.54%; N: 2.65%; Br: 15.16%; Cl: 6.72% found: C: 52.12%; H: 5.40%; N: 2.47%; Br: 14.77%; Cl:6.48%.
Step 5
Preparation of
SO3H
Figure imgf000068_0001
CH3
The crude product from Step 4 (-94 g) was taken up in absolute ethanol (180 mL) and para toluenesulfonic acid monohydrate (50.0 g, 0.26 mol) was added. The reaction mixture was then heated to reflux for 8 hours after which the solvent was removed under reduced pressure. The residual solid was taken up in THF (100 mL) and the THF was then stripped off under reduced pressure. The residue was dissolved in ethyl acetate (500 mL) and cooled to ~5X. The solid was filtered and washed with heptane (2 x 50 mL) to give a white solid. The solid was then air dried to give the desired product as a white solid (38 g) as a single isomer. 1H
66 NMR (DMSO, TMS) (ppm) 1.12 (t, 3H), 2.29 (s, 3H), 3.0 (m, 2H), 4.05 (q, 2H),4.88 (t, 1H), 7.11 (d, 2H), 7.48 (d, 2H), 7.55 (d, 1 H), 7.68 (1 H, d), 8.35 (br. s, 3H) ; 13C NMR (DMSO, TMS) (ppm):13.82, 20.75, 37.13, 45.59, 60.59, 110.63, 122.47, 125.44, 127.87, 128.06, 129.51, 131.95, 137.77, 145.33, 150.14, 168.98; DSC:69.86X (end., 406.5 J/g), 165.72X (end. 62.27 J/g), 211.24X (exo. 20.56 J/g) [α]D 25= + 4.2° (c =0.960,MeOH); IR (MIR) (cm-1 ) 2922, 1726, 1621 , 1591 , 1494, 1471 , 1413, 1376, 1324, 1286, 1237, 1207;. Microanalytical: calcd for C.βH∑iBrCINOeS:
C: 43.69%; H:4.27%; N: 2.83%; Br: 16.15%, Cl: 7.16%, S: 6.48% found: C: 43.40%; H:4.24%; N: 2.73%; Br: 16.40%, Cl: 7.20%, S: 6.54%.
Step 6
Preparation of
C02Et
^ ^ .NH. J
,OH
HCI
Br' 'Cl
The above compound was prepared according to the procedures outlined in Example I, Step 4 and Step 5 where an equivalent quantity of the intermediate prepared in Step 5 as the free base is substituted fin Example I, Step 4.
MS and 1H NMR were consistent with the desired structure.
67 EXAMPLE M
Preparation of
Hj.N'^γ ^C02Et
Step l xc
Preparation of 3-lodo-5-chlorosalicylaldehyde
N-lodosuccinimide (144.0 g, 0.641 mole) was added to a solution of 5-chlorosalicylaldehyde (100 g, 0.638 mole) in dimethylformamide (400 mL). The reaction mixture was stirred for 2 days at room temperature. Additional N-iodosuccinimide (20.0 g) was added and stirring was continued for additional 2 days. The reaction mixture was diluted with ethyl acetate (1L), washed with hydrochloric acid (300 mL, 0.1 N), water (300 mL), sodium thiosulfate (5%, 300 mL), brine (300 mL), dried (MgSO4) and was concentrated to dryness to afford the desired aldehyde as a pale yellow solid (162 g, 90% yield).
MS and 1H NMR were consistent with the desired structure.
Step 2
Preparation of 2-O-(MEM)-3-iodo-5-chlorosalicylaldehyde
Potassium carbonate (41.4 g, 0.30 mole) was added to a solution of 3-iodo-5-chlorosalicylaldehyde (84.74 g, 0.30 mole) in DMF (200 mL) at 20X. This resulted in a yellow slurry and MEM-CI (38.2 g, 0.305 mole) was added maintaining the reaction temperature. After 2 hours, additional MEM-CI (1.5 g) was added. After stirring for 1 hour, the reaction mixture was poured into an ice-water mixture and was stirred. The precipitate formed, was filtered, and was dried in vacuo to afford the desired protected aldehyde. Yield: 95 g (85%).
MS and 1H NMR were consistent with the desired structure.
68 Step 3
Preparation of
CO2.-BU
Figure imgf000071_0001
(S)-Phenyl glycinol (15.37 g, 0.112 mole) was added to a solution of 2-O-(MEM)-3-iodo-5-chlorosalicylaldehyde (41.5 g, 0.112 mole) in THF (200 mL) at room temperature. After 1 hour of stirring MgS04 (16 g) was added and the stirring was continued for 2 hours. The reaction mixture was filtered and the filtrate was concentrated and was dried in vacuo for 2 hours to obtain the desired intermediate imine. A 2-neck round bottomed flask was charged with the Reformatsky reagent from Example I, Step 1 , (81.8 g, 0.2464 mole) and N-methylpyrrolidone (300 mL) and was stirred at -10X. A solution of the imine in N-methylpyrrolidone (100 mL) was slowly added maintaining the temperature at -10X. The mixture was maintained at this temperature for 2 hours and for 1 hour at -5X. After cooling the reaction mixture to -10X, a solution of concentrated HCI in saturated ammonium chloride (16 ml/200 mL) was added. Ethyl ether (500 mL) was added and was stirred for 2 hours at room temperature. The ether layer was separated, and the aqueous layer was further extracted with ether (300 mL). The combined ether layers were washed with saturated ammonium chloride (200 mL), water (200 mL), brine (200 mL), dried (MgSO ) and concentrated to afford an oil (61.0 g, 90% yield). 1H NMR indicated that the desired structure was substantially one diastereomer and MS was consistent with the desired structure.
69 Step 4 Preparation of
Figure imgf000072_0001
Figure imgf000072_0002
A solution of the crude ester produced in Step 3 (48.85 g, 80.61 mmol) was dissolved in ethanol (500 mL) and was cooled to OX. Lead tetraacetate (35.71 g, 80.61 mmol) was added. After 3 hours, 15 % solution of NaOH (73 mL) was added to the reaction mixture. Most of the ethanol was removed under reduced pressure. To the residue was added a 15% solution of NaOH (200 mL) and which was then extracted with ether (400 mL). The ether layer was washed with water (100 mL), brine (100 mL), dried and was concentrated to afford an orange oil. The oil was dissolved in ethanol (100 mL) and para-toluenesulfonic acid (19.9 g) was added. The solution was heated at reflux for 8 hours and was concentrated under reduced pressure. The residue was diluted with THF (60 mL) and was heated at reflux and was cooled. The precipitate was filtered, washed with hexane THF (300 mL, 1 :1 )and dried to afford the desired product.
MS and 1H NMR were consistent with the desired structure. Step 5
S - Ethyl 3-(N-BOC-gly)-amino-3-(S)-(5-chloro-2-hydroxy-3-iodo)phenyl propionate
To a mixture of BOC-gly-OSu (9.4 g, 34.51 mmol), ethyl 3-(S)- amino-3-(5-chloro-2-hydroxy-3-iodo) propionate PTSA salt (17.0 g, 31.38 mmol) in DMF (200 mL) was added triethylamine (4.8 mL). The reaction mixture was stirred for 18 hours at room temperature. The DMF was removed in vacuo and the residue was partitioned between ethyl acetate
70 (600 mL) and diluted hydrochloric acid (100 mL). The organic layer was washed with sodium bicarbonate (200 mL), brine (200 mL), dried (MgSO4) and was concentrated to afford of the desired product as a solid (14.2 g, 86% yield). MS and 1H NMR were consistent with the desired structure.
Step 6
S - Ethyl 3-(N-gly)-amino-3-(5-chloro-2-hydroxy-3-iodo)phenyl propionate hydrochloride
Dioxane/HCI (4N, 70 mL) was added to ethyl 3-(S)-(N-BOC-gly)- amino-3-(5-chloro-2-hydroxy-3-iodo)phenyl propionate (37.20 g, 70.62 mmol) at OX and was stirred at room temperature for 3 hours. The reaction mixture was concentrated, and concentrated once more after addition of toluene (100 mL). The residue obtained was suspended in ether, was filtered and dried to afford the desired product as a crystalline powder (32.0 g, 98% yield).
MS and 1H NMR were consistent with the desired structure.
71 EXAMPLE N
Preparation of
H2N^ ^cC^Et
Br ^^ \ Br
Step l Preparation of
Figure imgf000074_0001
The above compound was prepared according to Example I, Step 2A, substituting an equivalent quantity of 2-hydroxy-3,5- dibromobenzaldehyde for 3,5-dichlorosalicylaldehyde.
Yield 88%; Pale yellow solid; m. p. 46-47 °C; R, = 0.6 (EtOAc/Hexane 1 :1 v/v); Η-NMR (CDCI3) d 3.37 (s, 3H), 3.56 (m, 2H), 3.92 (m, 2H), 5.29 (s, 2H), 7.91 (d, 1H, J = 2.4 Hz), 7.94 (d, 1H, J = 2.4 Hz), 10.27 (s, 1H); FAB- MS m/z 367 (M+) HR-MS calculated for Cι.H12Br2O4 367.9083 found 367.9077.
MS and H NMR were consistent with the desired structure.
Step 2
Figure imgf000074_0002
72 The above compound was prepared using the procedure of Example I, Step 2B and Step 2C, substituting an equivalent quantity of the compound of Step 1 in Example I, Step 2B.
Yield 90%; Yellow solid; m. p. 57-59 °C; R, = 0.46 (EtOAc/Hexane 1 :1 v/v); 1H-NMR (CDCb) d 1.45 (s, 9H); 2.1 (br, 1H, exchangeable), 2.51 (d, 1 H, J, = 9.9 Hz, J2 = 15.3 Hz), 2.66 (d, 1 H, J1 = 4.2 Hz, J2 = 15.3 Hz), 3.02 (br, 1H, exchangeable), 3.39 (s, 3H), 3.58 - 3.62 (m, 4H), 3.81 (m, 1H), 3.93 (m, 2H), 4.63 (dd, 1 H, J = 4.2 Hz), 5.15 (s, 2H), 7.17-7.25 (m, 6H), 7.49 (d, 1 H); FAB- MS m z 602 (M+H) HR-MS calculated for C25H3 NBr2O6 602.0753 found 602.0749.
MS and 1H NMR were consistent with the desired structure.
Step 3
Preparation of
Figure imgf000075_0002
Figure imgf000075_0001
CH3
The above compound (p-toluenesulfonate salt) was prepared according to Example 1, Step 3 by substituting an equivalent quantity of the product prepared in Step 2 in Example 1, Step 3A. Yield 62%; white solid; 1H-NMR (DMSO-d6) d 1.09 (t, 3H, J = 7.2 Hz), 2.27 (s, 3H), 2.97(dd, 2H, J, = 3.0 Hz, J2 = 7.2 Hz), 4.02 (q, 2H, J = 7.2 Hz), 4.87 (t, 1 H, J = 7.2 Hz), 7.08 (d, 2H, J = 4.8 Hz), 7.45 (m, 3H), 7.57 (d, 1 H, J = 2.4 Hz), 8.2 (br,3H); FAB-MS m/z 365 (M+H)
HR-MS calculated for CiiH14NBr2O3, 365.9340 found 365.9311.
MS and H NMR were consistent with the desired structure.
73 Step 4 Preparation of
H C02Et
H2N-"Y'
_OH
HCI
Rr' Br
The above compound was prepared using the procedure of Example I, Step 4 substituting the compound prepared in Step 3. The resulting BOC protected intermediate, was converted to the desired compound using the procedure of Example I, Step 5.
MS and 1H NMR were consistent with the desired structure.
74 EXAMPLE P
Preparation of
C02Et
H
H2N
OH
HCI
Br'
The above compound is prepared according to the procedure of Example I by substituting an equivalent amount of 3-iodo-5- bromosalicylaldehyde prepared in Example F, Step 1 for 3,5- dichlorosalicylaldehyde in Example I, Step 2 A.
75 EXAMPLE 1
(±) 3-bromo-5-chloro-2-hydroxy-β-[[2-[[[3-hydroxy-5-[(1 ,4,5,6- tetrahydro-5-hydroxypyrimidin-2-yl)amino]phenyl]carbonyl]amino]- acetyljaminojbenzenepropanoic acid, trifluroacetate salt
Preparation of
H
Figure imgf000078_0001
Figure imgf000078_0002
To the product of Example H (0.4 g, 0.0014 mole), the product of
Example B (0.58 g, 0.0014 mole), triethylamine (0.142 g, 0.0014 mole), DMAP (17 mg), and anhydrous DMA (4 ml) was added EDCI (0.268 g, 0.0014 mole) at ice bath temperature. The reaction was stirred overnight at room temperature. The resulting ester intermediate was isolated by reverse phase preparatory HPLC. To this ester in H2O (10 ml) and CH3CN (5 ml) was added LiOH (580 mg, 0.0138 mole). After stirring at room temperature for 1 hour, the pH was lowered to 2 with TFA and the product was purified by reverse phase preparatory HPLC to yield (after lyophilization) the desired product as a white solid (230 mg). MS and 1H NMR were consistent with the desired structure.
76 EXAMPLE 2 Preparation of
H
0 ∞
Figure imgf000079_0001
cr Λλ 1
The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product from Example A for the product from Example B. The yield, after lyophiiization was 320 mg of as a white solid. MS and 1H NMR were consistent with the desired structure.
77 EXAMPLE 3
Preparation of
π XΥ *C02H ,OH
Figure imgf000080_0001
Br'
The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product from Example F for the product from Example B. The yield (after lyophiiization) was 180 mg as a white solid. MS and 1H NMR were consistent with the desired structure.
78 EXAMPLE 4 Preparation of
H κ"Y 'C^H -OH
Figure imgf000081_0001
Br' 'Cl
The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product of Example D for the product of Example B. The yield (after lyophiiization) was 180 mg as a white solid. MS and 1H NMR were consistent with the desired structure.
79 EXAMPLE 5 Preparation of
C02H
N
Figure imgf000082_0001
OH
HO ' ■B
OH cr
The above compound was prepared according to the methodology of Example 1, substituting an equivalent amount of the product from Example E for the product from Example B. The yield (after lyophiiization) was 250 mg as a white solid. MS and 1H NMR were consistent with the desired structure.
80 EXAMPLE 6 Preparation of
H N, κ"Y 'COjH ,OH
Figure imgf000083_0001
Br' *Br
The above compound was prepared according to the methodology of Example 1 , substituting an equivalent amount of the product from Example C for the product from Example B. The yield (after lyophiiization) was 220 mg as a white solid. MS and Η NMR were consistent with the desired product.
EXAMPLE 7
Preparation of
Figure imgf000084_0001
Figure imgf000084_0002
To the product from Example H (7.8 g, 0.027 mole) dissolved in anhydrous DMA (50 mL) in a flame dried flask under N2 and at ice bath temperature was slowly added isobutylchloroformate (3.7 g, 0.027 mole) followed by N-methylmorphoiine (2.73 g, 0.027 mole). The solution was stirred at ice bath temperature for 15 minutes. To the reaction mixture was then added the product from Example L (10.0 g, 0.024 mole) at ice bath temperature followed by N-methylmorpholine (2.43 g, 0.024 mole). The reaction was then stirred at room temperature overnight. The resulting ester intermediate was isolated by reverse phase prep HPLC. To the ester in H20 (60 mL) and CH3CN (30 mL ) was added LiOH (10 g, 0.238 mole). The reaction mixture was stirred at room temperature for 1 hour. The pH was then lowered to 2 with TFA. The product was purified by reverse phase prep HPLC to yield (after lyophiiization) the desired product as a white solid (9.7 g). MS and Η NMR were consistent with the desired structure.
82 EXAMPLE 8
(S) 3,5-dichloro-2-hydroxy-β-[[2-[[[3-hydroxy-5-[(1 ,4,5,6-tetrahydro-5- hydroxypyrimidin-2-yl)amino]phenyl]carbonyl]amino]acetyl]amino]- benzenepropanoic acid, monohydrochloride monohydrate
Preparation of
HCI
Figure imgf000085_0001
Step A To the product from Example H (9.92 g, 0.0345 mole) dissolved in anhydrous DME (200 mL) is added N-methylmorpholine (4.0 mL, 0.0362 mole). The reaction mixture was cooled to -5X (salt-ice bath). Isobutylchloroformate, IBCF (4.48 mL, 4.713 g, 0.0345 mole) was added over one minute and the reaction mixture stirred at ice bath temperature for 12 minutes. To the reaction mixture was then added the product from Example I (11.15 g, 0.030 mole) at ice bath temperature followed by N- methylmorpholine (4.0 mL, 0.0362 mole). The reaction mixture was allowed to warm to room temperature and go to completion then concentrated under vacuum at 50X to give a dark residue. The residue was dissolved in acetonitrile : H20 (about 50 mL). The pH was made acidic by addition of a small amount of TFA. The residue was placed on a 10 x 500 cm C-18 (50 u particle size) column and the ester of the desired product isolated. (Solvent program: 100% H2O + 0.05% TFA to 30:70 H2O + 0.05% TFA : acetonitrile + 0.05% TFA over 1 hour @ 100 mUminute: the solvent program was initiated after the solvent front elutes). Preparatory RPHPLC purification resulted in a white solid (10.5 g) after lyophiiization (50%).
MS and 1H NMR were consistent with the desired structure.
83 Step B
The product produced in Step A (about 11 g) was dissolved in dioxane : water and the pH of the solution adjusted to approximately 11.5 (pH meter) by the addition of 2.5 N NaOH. The reaction mixture was stirred at room temperature. Periodically, the pH was re-adjusted to > 11 by further addition of base. After 2-3 hours the conversion of ester to acid was deemed complete by RPHPLC. The pH of the reaction mixture was adjusted to about 6 and a viscous oil precipitated from solution. The oil was isolated by decantation and washed with hot water (200 mL). The resulting aqueous mixture was allowed to cool and the solid was collected by filtration to yield The above compound (2.6 g after lyophiiization from HCI solution). The residue, which was a dark viscous oil was treated with hot water to give on cooling a tan powder (4.12 g after lyophiiization from HCI solution). MS and 1H NMR were consistent with the desired structure.
84 EXAMPLE 9
(S) 3-bromo-5-chloro-2-hydroxy-β-[[2-[[[3-hydroxy-5-[(1 ,4,5,6-tetrahydro-5- hydroxypyrimidin-2-yl)amino]phenyl]carbonyl]amino]acetyl]amino]- benzenepropanoic acid, trifluoroacetate salt
Step 1 - Preparation of
H
Figure imgf000087_0001
Figure imgf000087_0002
To a suspension of the product from Example J (1.0 g, 2.4 mmol), the product from Example H (0.75 g, 2.6 mmol) and 4- dimethylaminopyridine (40 mg) in N,N-dimethylacetamide (10 mL) was added triethylamine (0.24 g, 2.4 mmol). The mixture was stirred at room temperature for 15 minutes and 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (0.60 g, 3.1 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and purified by reverse phase HPLC (starting gradient 90:10 H2O/TFA:MeCN, retention time 22 minutes) to give the desired product, (1.6 g, 52% yield).
1H NMR was consistent with the proposed structure.
Step 2
TFA
Figure imgf000087_0003
85 To a solution of the ester produced in Step 1 (800 mg, 1.2 mmol) in a 1 :4 MeCN:H O solution (7 mL) was added lithium hydroxide (148 mg, 6.2 mmol). The reaction mixture was stirred at room temperature for 2 hours. TFA (0.71 mL, 9.2 mmol) was added and the mixture purified by reverse phase HPLC (starting gradient 95:5 H20/TFA:MeCN, retention time 24 minutes) to give the desired product (860 mg, 83% yield). Anal, calcd for C22H23BrCIN5O7 + 1.7 TFA:
C, 39.18; H, 3.20; N, 8.99. Found: C, 39.11 ; H, 3.17; N, 9.07. MS and 1H NMR were consistent with the desired structure.
Step 3
Preparation of the hydrochloride salt
The product of Step 2 was dissolved in a suitable solvent
(acetontrile : water) and the solution slowly passed through a Bio-Rad AG2 - 8X (chloride form, 200 - 400 mesh, > 5 equivalents) ion-exchange column. Lyophiiization gives the desired product as an HCI salt.
86 EXAMPLE 10
Preparation of
Figure imgf000089_0001
The above compound was prepared using the procedure of Example 8 substituting the product of Example N for the product of Example I in Example 8, Step A. The product was isolated by prep RPHPLC and lyophilized to give the desired product as a TFA salt.
MS and 1H NMR were consistent with the desired structure.
87 EXAMPLE 11
Preparation of
H
Figure imgf000090_0001
Figure imgf000090_0002
The above compound was prepared using essentially the procedures of Example 8 and substituting the product of Example M for the product of Example I in Example 8, Step A. The product was isolated by preparatory RPHPLC and lyophilized to give the desired product as a TFA salt.
MS and H NMR were consistent with the desired structure.
EXAMPLE 12
Preparation of
Figure imgf000091_0001
The above compound was prepared using the procedures of Example 8 and substituting the product of Example P for the product of Example I in Example 8, Step A. The product is isolated by prep RPHPLC and lyophilized to give the desired product as a TFA salt.
89 EXAMPLE 13
Preparation of
H
Figure imgf000092_0001
Figure imgf000092_0002
Preparation of 2-0-(MEM)-3,5-diiodosalicylaldehyde
CHO
Figure imgf000092_0003
Potassium carbonate (18.5 g, 0.134 mole) was added to a solution of 3,5-diiodosalicylaldehyde (50.0 g, 0.134 mole) in DMF (150 mL) at 20X. This resulted in a yellow slurry and MEM-CI (15.8 mL, 0.134 mole) was added maintaining the reaction temperature. After 2 hours, additional MEM-CI (1.5 g) was added. After stirring for a further 1 hour, the reaction mixture was poured into ice-water and stirred. The precipitate formed, was filtered, and dried in vacuo to afford the desired protected aldehyde (61 g, 99% yield). 1H NMR was consistent with the desired product.
Step 2 Preparation of
Figure imgf000092_0004
90 (S)-phenyl glycinol (17.9 g, 0.13 mole) was added to a solution of 2- 0-(MEM)-3,5-diiodosalicylaldehyde (41.5 g, 0.112 mole) in THF (150 mL) at room temperature. After 1 hour of stirring MgSO4 (20.7 g) was added and the stirring was continued for 2 hours. The reaction mixture was filtered and the filtrate was concentrated and dried in vacuo for 2 hours. A 2-neck round bottomed flask was charged with the Reformatsky reagent (96 g, 0.289 mole) and N-methylpyrrolidone (250 mL) and was stirred at -10X. A solution of the imine in N-methylpyrrolidone (100 mL) was slowly added maintaining the temperature at -10°C. The mixture was maintained at this temperature for 2 hours and for 1 hour at -5X. After cooling the reaction mixture to -10X, a solution of concentrated HCI in saturated ammonium chloride (16 ml/200 mL) was added. Ethyl ether (500 mL) was added and the mixture was stirred for 2 hours at room temperature. The ether layer was separated, and the aqueous layer further extracted with ether (300 mL). The combined ether layers were washed with saturated ammonium chloride (200 mL), water (200 mL), brine (200 mL), dried (MgSO4) and concentrated to afford an oil (90.0 g, 99% yield). NMR indicated desired product and one diastereomer.
Step 3
Preparation of
Figure imgf000093_0001
A solution of the crude ester from Step 2 (14.0 g, 20.1 mmol) was dissolved in ethanol (100 mL) and was cooled to 0°C. Lead tetra acetate (9.20 g, 20.75 mmol) was added in one lot. After 3 hours, 15% solution of NaOH (73 mL) was added to the reaction mixture. Most of the ethanol was
91 removed under reduced pressure. The residue was added to a 15% solution of NaOH (200 mL) which was extracted with ether (400 mL). The ether layer was washed with water (100 mL), brine (100 mL), dried and concentrated to afford an orange oil. This was dissolved in ethanol (100 mL) and para-toluenesulfonic acid (6.08 g) was added. The solution was heated at reflux for 8 hours and was concentrated under reduced pressure. The residue was diluted with THF (60 mL), was heated at reflux and was cooled. Upon storage, no precipitate formed. The reaction mixture was concentrated and purified by preparative hplc to afford the amino acid as its PTSA salt. The solid obtained was dissolved in ethanol and was saturated with HCI gas. The reaction mixture was heated at reflux for 6 hours. The reaction mixture was concentrated to afford the PTSA salt of the desired amino acid (12.47 g).
Step 4
Preparation of Ethyl 3-(N-BOC-gly)-amino-3-(S)-(3,5-diiodo-2 hydroxyphenyl)propionate
-^^O^^NH^Y ^ r^^COOH
Figure imgf000094_0002
O ^ . .OH
Figure imgf000094_0001
To a mixture of BOC-gly-OSu (7.48 g, 27.04 mmol), ethyl 3-(S)- amino-3-(3,5-diiodo-2-hydroxyphenyl)propionate PTSA salt (12.47g, 27.04 mmol) in DMF (100 mL) was added triethylamine (3.8 mL). The reaction mixture was stirred for 18 hours at room temperature. The DMF. was removed in vacuo and the residue partitioned between ethyl acetate (600 mL) and dilute hydrochloric acid (100 mL). The organic layer was washed with sodium bicarbonate (200 mL), brine (200 mL), dried (MgSO4) and concentrated to afford the desired product as a solid (17.0 g, 96% yield). 1H NMR was consistent with the desired product.
92 Step 5
Preparation of ethyl 3-(N-gly)-amino-3-(3,5-diiodo-2-hydroxyphenyl)- propionate hydrochloride
Figure imgf000095_0001
To dioxane/HCI (4N, 40 mL) was added ethyl 3-(N-BOC-gly)-amino- 3-(S)-(3,5-diiodo-2-hydroxyphenyl)ρropionate (17.0 g, 25.97 mmol) at OX and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated, and concentrated once more after addition of toluene (100 mL). The residue obtained was dried to afford the desired product as a crystalline powder (8.0 g, 56% yield). 1H NMR is consistent with the desired product.
Step 6 A solution of m-(5-hydroxypyrimidino)hippuric acid (3.74 g, 12.98 mmol) in dimethylacetamide (25 mL) was heated until all the material had dissolved. This was then cooled to OX and isobutylchloroformate (1.68 mL) was added in one portion followed by N-methylmorpholine (1.45 mL). After 10 minutes, ethyl 3-(N-gly)-amino-3-(3,5-diiodo-2-hydroxyphenyl)- propionate hydrochloride (6.0 g, 10.82 mmol) was added in one portion followed by N-methylmorpholine (1.45 mL). The reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was concentrated, the residue dissolved in tetrahydrofuran/water (1 :1 , 20mL), and was chromatographed (reverse phase, 95:5 water: acetonitrile over 60 minutes to 30:70 water: acetonitrile containing 0.1 % TFA). The combined fractions were concentrated. The residue was dissolved in acetonitrile water and lithium hydroxide was added until basic. The solution was stirred for 2 hours. The reaction mixture was concentrated and was
93 purified as above by hplc to afford the desired acid as the TFA salt. The TFA salt was converted to the corresponding hydrochloride salt by passing through an ion-exchange column followed by lyophiiization. 1H NMR was consistent with the desired product.
94 EXAMPLES 14-18
The compounds of the formula VII, Nm, IX, xm and XIN and isomers thereof, can be prepared according to the methodology disclosed herein substituting the appropriate starting materials and reagents as would be apparent to one with ordinary skill in the art.
95 The activity of the compounds of the present invention was tested in the following assays. The results of testing in the assays are tabulated in Table 1.
VITRONECTIN ADHESION ASSAY MATERIALS
Human vitronectin receptor (αvβs) was purified from human placenta as previously described [Pytela et al., Methods in Enzvmoloαv. 1 4:475- 489 (1987)]. Human vitronectin was purified from fresh frozen plasma as previously described [Yatohgo et al., Cell Structure and Function. 13:281 - 292 (1988)]. Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to purified vitronectin as previously described [Charo et al., J. Biol. Chem., 266(3):1415-1421 (1991 )]. Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO). Anti-biotin antibody was obtained from Calbiochem (La Jolla, CA). Linbro microtiter plates were obtained from Flow Labs (McLean, VA). ADP reagent was obtained from Sigma (St. Louis, MO).
METHODS
Solid Phase Receptor Assays This assay was essentially the same as previously reported [Niiya et al., Blood. 70:475-483 (1987)]. The purified human vitronectin receptor (αvβ3) was diluted from stock solutions to 1.0 g/mL in tris-buffered saline containing 1.0 mM Ca++, Mg++, and Mn++, pH 7.4 (TBS+++). The diluted receptor was immediately transferred to Linbro microtiter plates at 100 Uwell (100 ng receptor/well). The plates were sealed and incubated overnight at 4X to allow the receptor to bind to the wells. All remaining steps were at room temperature. The assay plates were emptied and 200 L
96 of 1% RIA grade BSA in TBS+++ (TBS+++/BSA) were added to block exposed plastic surfaces. Following a 2 hour incubation, the assay plates were washed with TBS+++ using a 96 well plate washer. Logarithmic serial dilution of the test compound and controls were made starting at a stock concentration of 2 mM and using 2 nM biotinylated vitronectin in
TBS+++/BSA as the diluent. This premixing of labeled ligand with test (or control) ligand, and subsequent transfer of 50 L aiiquots to the assay plate was carried out with a CETUS Propette robot; the final concentration of the labeled ligand was 1 nM and the highest concentration of test compound was 1.0 x 10" M. The competition occurred for two hours after which all wells were washed with a plate washer as before. Affinity purified horseradish peroxidase labeled goat anti-biotin antibody was diluted 1 :3000 in TBS+++/BSA and 125 L were added to each well. After 30 minutes, the plates were washed and incubated with OPD/H2O substrate in 100 mM/L Citrate buffer, pH 5.0. The plate was read with a microtiter plate reader at a wavelength of 450 nm and when the maximum-binding control wells reached an absoround bottomance of about 1.0, the final A450 were recorded for analysis. The data were analyzed using a macro written for use with the EXCEL spreadsheet program. The mean, standard deviation, and %CV were determined for duplicate concentrations. The mean A450 values were normalized to the mean of four maximum-binding controls (no competitor added)(B-MAX). The normalized values were subjected to a four parameter curve fit algorithm [Rodbard et al., Int. Atomic Energy Agency. Vienna, pp 469 (1977)], plotted on a semi-log scale, and the computed concentration corresponding to inhibition of 50% of the maximum binding of biotinylated vitronectin (IC50) and corresponding R2 was reported for those compounds exhibiting greater than 50% inhibition at the highest concentration tested; otherwise the IC50 is reported as being greater than the highest concentration tested. β-[[2-[[5-[(aminoiminomethyl)-amino]-1- oxopentyl]amino]-1-oxoethyl]amino]-3-ρyridineρropanoic acid [USSN
08/375,338, Example 1] which is a potent αvβ3 antagonist (IC50 in the range 3-10 nM) was included on each plate as a positive control.
97 PURIFIED llb/llla RECEPTOR ASSAY
MATERIALS
Human fibrinogen receptor (αnbβ3) was purified from outdated platelets. (Pytela, R., Pierschbacher, M.D., Argraves, S., Suzuki, S., and Rouslahti, E. "Arginine-Glycine-Aspartic acid adhesion receptors", Methods in Enzvmology 144(1987):475-489.) Human vitronectin was purified from fresh frozen plasma as described in Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M., "Novel purification of vitronectin from human plasma by heparin affinity chromatography," Cell Structure and Function 13(1988):281-292. Biotinylated human vitronectin was prepared by coupling NHS-biotin from Pierce Chemical Company (Rockford, IL) to purified vitronectin as previously described. (Charo, I.F., Nannizzi, L., Phillips, D.R., Hsu, M.A., Scaround bottomorough, R.M., "Inhibition of fibrinogen binding to GP llb/llla by a GP Ilia peptide", J. Biol. Chem.
266(3)(1991): 1415-1421.) Assay buffer, OPD substrate tablets, and RIA grade BSA were obtained from Sigma (St. Louis, MO). Anti-biotin antibody was obtained from Calbiochem (La Jolla, CA). Linbro microtiter plates were obtained from Flow Labs (McLean, VA). ADP reagent was obtained from Sigma (St. Louis, MO).
METHODS
Solid Phase Receptor Assays
This assay is essentially the same reported in Niiya, K., Hodson, E., Bader, R., Byers-Ward, V. Koziol, J.A., Plow, E.F. and Ruggeri, Z.M., "Increased surface expression of the membrane glycoprotein llb/llla complex induced by platelet activation: Relationships to the binding of fibrinogen and platelet aggregation", Blood 70(1987):475-483. The purified human fibrinogen receptor (αnbβ3) was diluted from stock solutions to 1.0 μg/mL in Tris-buffered saiine containing 1.0 mM Ca++, Mg++, and
98 Mn++, pH 7.4 (TBS+++). The diluted receptor was immediately transferred to Linbro microtiter plates at 100 μUwell (100 ng receptor/well). The plates were sealed and incubated overnight at 4X to allow the receptor to bind to the wells. All remaining steps were at room temperature. The assay plates were emptied and 200 μL of 1 % RIA grade BSA in TBS+++ (TBS+++/BSA) were added to block exposed plastic surfaces. Following a 2 hour incubation, the assay plates were washed with TBS+++ using a 96 well plate washer. Logarithmic serial dilution of the test compound and controls were made starting at a stock concentration of 2 mM and using 2 nM biotinylated vitronectin in TBS+++/BSA as the diluent. This premixing of labeled ligand with test (or control) ligand, and subsequent transfer of 50 μL aliquots to the assay plate was carried out with a CETUS Propette robot; the final concentration of the labeled ligand was 1 nM and the highest concentration of test compound was 1.0 x 10"4 M. The competition occurred for two hours after which all wells were washed with a plate washer as before. Affinity purified horseradish peroxidase labeled goat anti-biotin antibody was diluted 1 :3000 in TBS+++/BSA and 125 μL were added to each well. After 30 minutes, the plates were washed and incubated with ODD/H2O2 substrate in 100 mM/L citrate buffer, pH 5.0. The plate was read with a microtiter plate reader at a wavelength of 450 nm and when the maximum-binding control wells reached an absoround bottomance of about 1.0, the final A450 were recorded for analysis. The data were analyzed using a macro written for use with the EXCEL™ spreadsheet program. The mean, standard deviation, and %CV were determined for duplicate concentrations. The mean A450 values were normalized to the mean of four maximum-binding controls (no competitor added)(B-MAX). The normalized values were subjected to a four parameter curve fit algorithm, [Robard et al., Int. Atomic Energy Agency. Vienna, pp 469 (1977)], plotted on a semi-log scale, and the computed concentration corresponding to inhibition of 50% of the maximum binding of biotinylated vitronectin (IC50) and corresponding R2 was reported for
99 those compounds exhibiting greater than 50% inhibition at the highest concentration tested; otherwise the IC50 is reported as being greater than the highest concentration tested. β-[[2-[[5-[(aminoiminomethyl)amino]-1- oxopentyl]amino]-1 -oxoethyl]amino]-3-pyridinepropanoic acid [USSN 08/375,338, Example 1 ] which is a potent αvβ3 antagonist (ICso)in the range 3-10 nM) was included on each plate as a positive control.
Human Platelet Rich Plasma Assays
Healthy aspirin free donors were selected from a pool of volunteers. The harvesting of platelet rich plasma and subsequent ADP induced platelet aggregation assays were performed as described in Zucker, M.B., "Platelet Aggregation Measured by the Photometric Method", Methods in Enzvmoloov 169(1989):117-133. Standard venipuncture techniques using a butterfly allowed the withdrawal of 45 mL of whole blood into a 60 mL syringe containing 5 mL of 3.8% trisodium citrate. Following thorough mixing in the syringe, the anti-coagulated whole blood was transferred to a 50 mL conical polyethylene tube. The blood was centrifuged at room temperature for 12 minutes at 200 mg to sediment non-platelet cells. Platelet rich plasma was removed to a polyethylene tube and stored at room temperature until used. Platelet poor plasma was obtained from a second centrifugation of the remaining blood at 2000 xg for 15 minutes. Platelet counts are typically 300,000 to 500,000 per microtiter. Platelet rich plasma (0.45 mL) was aliquoted into siliconized cuvettes and stirred (1100 rpm) at 37X for 1 minute prior to adding 50 uL of pre-diluted test compound. After 1 minute of mixing, aggregation was initiated by the addition of 50 uL of 200 uM ADP. Aggregation was recorded for 3 minutes in a Payton dual channel aggregometer (Payton Scientific, Buffalo, NY). The percent inhibition of maximal response (saline control) for a series of test compound dilutions was used to determine a dose response curve. All compounds were tested in duplicate and the concentration of half-maximal inhibition (IC50) was calculated graphically from the dose response curve for those compounds which exhibited 50% or greater inhibition at the
100 highest concentration tested; otherwise, the IC50 is reported as being greater than the highest concentration tested.
αvβ3 πb ma
Example ICso (nM) ICeo (nM)
1 0.88 310
2 1.04 430
3 23.7 2440
4 2.02 575
5 2.13 744
6 6.46 919
7 1.01 262
8 0.40 131
9 0.37 388
9 «HCI 0.82 226.2
10 2.26 641
11 - -
Figure imgf000103_0001
12 9.59 1060
101

Claims

What is claimed is:
1. A compound of the formula
Figure imgf000104_0001
wherein X and Y are the same or different halo group; R Is H or lower alkyl; and pharmaceutically acceptable salts thereof.
2. A compound according to Claim 1 selected from the group consisting of:
H
Figure imgf000104_0002
Figure imgf000104_0003
Figure imgf000104_0004
Figure imgf000104_0005
102 H H
CO2R
,N OH ;
OH
Figure imgf000105_0001
Br' XI
H rV O2R
.OH ;
HO^^
Figure imgf000105_0002
y
OH
H H H ^YN ^C02R
,N
HO' -V H 0 JL^ .ΓO-H :
Figure imgf000105_0003
OH
Br Εr
H H o H
XO2R
H OH ;
HO'
H H
Figure imgf000105_0004
O2R ,N O .OH ;
HO'
OH
'Br
103 H H
,N ;
Figure imgf000106_0001
H
NH_
CO2R OH ; O
Figure imgf000106_0002
Or
Figure imgf000106_0003
OH
B Cl
H 8 L" ;
Figure imgf000106_0004
XI
O
H H H
Figure imgf000106_0005
CC^R
.N OH ;
HO'
OH
H H ,N. NH O2R
.N
HO' H 5 .OH ;
OH y ^^ "Br
104 HO' xyX ;
OH
Cl
Figure imgf000107_0001
; and
Figure imgf000107_0002
H H
HO' Y ,N ;
Figure imgf000107_0003
OH
Figure imgf000107_0004
wherein R is H or alkyl; or pharmaceutically acceptable salts thereof.
A compound according to Claim 1 selected from the group consisting of
H H H
Figure imgf000107_0005
O2H
,N .OH ;
HO'
OH
105 H
CO2H
OH ;
Figure imgf000108_0001
Figure imgf000108_0002
H H
,N Γûáo ;
OH
Br
Figure imgf000108_0003
H H H N
Figure imgf000108_0005
N^^ CC^H .OH ;
HO
Figure imgf000108_0004
OH
Br
Figure imgf000108_0006
O
H H -NL ^ . C^H
-N O ,OH ;
HO'
Figure imgf000108_0007
OH Br' Εr
106
Figure imgf000109_0001
H H "' XO2H
,N .OH '
Figure imgf000109_0002
OH
Εr
Figure imgf000109_0003
H
NH-
Figure imgf000109_0004
XO2H
,N .OH ;
OH
C ^^ ^Cl
107 H
CO2H
,N OH ;
Figure imgf000110_0001
OH
Figure imgf000110_0002
Cl' "Br
H
NH_ O2H
_ r^Y* Or OH :
Figure imgf000110_0003
OH
B Εr
H
,N ;
Figure imgf000110_0004
OH
Cl
Figure imgf000110_0005
and
Figure imgf000110_0006
H ,N
Figure imgf000110_0007
-N '
Figure imgf000110_0008
OH
Figure imgf000110_0009
108
4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 2 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 3 and a pharmaceutically acceptable carrier.
7. A method for treating conditions mediated by the ╬▒v╬▓╬▓ integrin in a mammal in need of such treatment comprising administering an effective o_v╬▓3 inhibiting amount of a compound according to Claim !
8. A method for treating conditions mediated by the ╬▒v╬▓3 integrin in a mammal in need of such treatment comprising administering an effective oy╬▓3 inhibiting amount of a compound according to Claim 2.
9. A method for treating conditions mediated by the ov╬▓╬▓ integrin in a mammal in need of such treatment comprising administering an effective c_v╬▓3 inhibiting amount of a compound according to Claim 3.
10. A method according to Claim 7 wherein the condition treated is tumor metastasis.
11. A method according to Claim 8 wherein the condition treated is tumor metastasis.
12. A method according to Claim 9 wherein the condition treated is tumor metastasis.
109
13. A method according to Claim 7 wherein the condition treated is solid tumor growth.
14. A method according to Claim 8 wherein the condition treated is solid tumor growth.
15. A method according to Claim 9 wherein the condition treated is solid tumor growth.
16. A method according to Claim 7 wherein the condition treated is angiogenesis.
17. A method according to Claim 8 wherein the condition treated is angiogenesis.
18. A method according to Claim 9 wherein the condition treated is angiogenesis.
19. A method according to Claim 7 wherein the condition treated is osteoporosis.
20. A method according to Claim 8 wherein the condition treated is osteoporosis.
21. A method according to Claim 9 wherein the condition treated is osteoporosis.
22. A method according to Claim 7 wherein the condition treated is humoral hypercalcemia of malignancy.
10
23. A method according to Claim 8 wherein the condition treated is humoral hypercalcemia of malignancy.
24. A method according to Claim 9 wherein the condition treated is humoral hypercalcemia of malignanc
25. A method according to Claim 7 wherein the condition treated is smooth muscle cell migration.
26. A method according to Claim 8 wherein the condition treated is smooth muscle cell migration.
27. A method according to Claim 9 wherein the condition treated is smooth muscle cell migration.
28. A method according to Claim 7 wherein restenosis is inhibited.
29. A method according to Claim 8 wherein restenosis is inhibited.
30. A method according to Claim 9 wherein restenosis is inhibited.
31. A method according to Claim 7 wherein the condition treated is rheumatoid arthritis.
32. A method according to Claim 8 wherein the condition treated is rheumatoid arthritis.
33. A method according to Claim 9 wherein the condition treated is rheumatoid arthritis.
34. A method according to Claim 7 wherein the condition treated is macular degeneration.
n :
35. A method according to Claim 8 wherein the condition treated is macular degeneration.
36. A method according to Claim 9 wherein the condition treated is macular degeneration.
112
PCT/US1999/003281 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists WO1999044994A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
PL99342726A PL342726A1 (en) 1998-03-04 1999-02-22 Metha-azacyclic compounds of aminobenzoic acid and their derivatives constituting antagonists of integrins
KR1020007009774A KR20010041584A (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
EP99937927A EP1060164A1 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
CA002322207A CA2322207A1 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
JP2000534538A JP2002505323A (en) 1998-03-04 1999-02-22 Meta-azacyclic aminobenzoic compounds and their derivatives as integrin antagonists
APAP/P/2000/001893A AP1244A (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists.
IL13765399A IL137653A0 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
SK1300-2000A SK13002000A3 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
HU0100865A HUP0100865A3 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists, pharmaceutical compositions comprising thereof and their use
OA1200000238A OA11530A (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists.
UA2000095148A UA71906C2 (en) 1998-03-04 1999-02-22 Meta-azacyclic compounds of aminobenzoic acid and derivatives thereof being integrin inhibitors
BR9908470-8A BR9908470A (en) 1998-03-04 1999-02-22 Compound, pharmaceutical composition, and process to treat conditions mediated by avb3 inegrin in a mammal in need of such treatment
AU32947/99A AU753230B2 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
EA200000804A EA200000804A1 (en) 1998-03-04 1999-02-22 META-AZACLIC COMPOUNDS OF AMINOBENZOIC ACID AND THEIR DERIVATIVES, WHICH ARE INTEGRINE INHIBITORS
EEP200000506A EE200000506A (en) 1998-03-04 1999-02-22 Meta-azacyclic aminobenzoic acid compounds and their derivatives as integrin antagonists
IS5582A IS5582A (en) 1998-03-04 2000-08-04 Meta-azahringaminobenzoic acid compounds and their derivatives prove to be antagonists of integrin.
NO20004316A NO315703B1 (en) 1998-03-04 2000-08-30 Meta azacyclic aminobenzoic acid compounds and derivatives thereof which are integrin antagonists
BG104740A BG104740A (en) 1998-03-04 2000-09-01 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
HR20000574A HRP20000574A2 (en) 1998-03-04 2000-09-01 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3427098A 1998-03-04 1998-03-04
US09/034,270 1998-03-04

Publications (1)

Publication Number Publication Date
WO1999044994A1 true WO1999044994A1 (en) 1999-09-10

Family

ID=21875345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003281 WO1999044994A1 (en) 1998-03-04 1999-02-22 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists

Country Status (29)

Country Link
EP (1) EP1060164A1 (en)
JP (1) JP2002505323A (en)
KR (1) KR20010041584A (en)
CN (1) CN1214011C (en)
AP (1) AP1244A (en)
AR (1) AR018139A1 (en)
AU (1) AU753230B2 (en)
BG (1) BG104740A (en)
BR (1) BR9908470A (en)
CA (1) CA2322207A1 (en)
EA (1) EA200000804A1 (en)
EE (1) EE200000506A (en)
GE (1) GEP20033118B (en)
HR (1) HRP20000574A2 (en)
HU (1) HUP0100865A3 (en)
ID (1) ID25591A (en)
IL (1) IL137653A0 (en)
IS (1) IS5582A (en)
MY (1) MY123908A (en)
NO (1) NO315703B1 (en)
NZ (1) NZ506598A (en)
OA (1) OA11530A (en)
PL (1) PL342726A1 (en)
SK (1) SK13002000A3 (en)
TR (1) TR200002542T2 (en)
UA (1) UA71906C2 (en)
WO (1) WO1999044994A1 (en)
YU (1) YU52000A (en)
ZA (1) ZA994406B (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329362B1 (en) 1998-03-16 2001-12-11 Celltech Therapeutics Limited Cinnamic acid derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
US6465471B1 (en) 1998-07-03 2002-10-15 Celltech Therapeutics Limited Cinnamic acid derivatives
US6469025B1 (en) 2000-08-02 2002-10-22 Celltech R&D Ltd. 3-substituted isoquinolin-1-yl derivatives
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6610700B2 (en) 2000-04-17 2003-08-26 Celltech R & D Limited Enamine derivatives
US6677339B2 (en) 1998-09-28 2004-01-13 Celltech R & D Limited Phenylalanine derivatives
WO2004060376A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
US6953798B1 (en) 1998-11-30 2005-10-11 Celltech R&D Limited β-alanine derivates
WO2005120477A2 (en) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
EP1904468A2 (en) * 2005-06-10 2008-04-02 Bipar Sciences, Inc. Parp modulators and treatment of cancer
US8313729B2 (en) 2007-03-01 2012-11-20 Medibeacon, LLC Integrated photoactive small molecules and uses thereof
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
US9085606B2 (en) 2012-07-18 2015-07-21 Saint Louis University Beta amino acid derivatives as integrin antagonists
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
US10035778B2 (en) 2015-12-30 2018-07-31 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
WO2021230325A1 (en) 2020-05-14 2021-11-18 宇部興産株式会社 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023085396A1 (en) 2021-11-12 2023-05-19 Ｕｂｅ株式会社 Pharmaceutical composition for providing treatment for or preventing alport syndrome

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4792124B1 (en) * 2010-11-15 2011-10-12 エフイートレード株式会社 Method for molding protective film for vehicle and method for manufacturing protective film for vehicle
BR112016028370B1 (en) * 2014-06-04 2021-03-09 Monsanto Technology Llc process for the preparation of 3,6-dichlorosalicylic acid compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008145A1 (en) * 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008145A1 (en) * 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FIELDS,G.B.: "Integrins: cell adhesion molecules in cancer", EXP.OPIN.THER.PATENTS, vol. 8, no. 6, August 1998 (1998-08-01), LONDON, pages 633 - 644, XP002105988 *
HONG,H. ET AL.: "Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching", J.MED.CHEM., vol. 40, no. 6, 1997, WASHINGTON, pages 930 - 936, XP002105987 *
NICKLAUS,M.C. ET AL.: "HIV-1 Integrase Pharmacophore: Discovery of Inhibitors through Three-Dimensional Database Searching", J.MED.CHEM., vol. 40, no. 6, 1997, WASHINGTON, pages 920 - 929, XP002105986 *
POMMIER,Y. ET AL.: "HIV-1 Integrase as a target for antiviral drugs", ANTIVIRAL CHEM.CHEMOTHER., vol. 8, no. 6, 1997, AMSTERDAM, pages 463 - 483, XP002105985 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329362B1 (en) 1998-03-16 2001-12-11 Celltech Therapeutics Limited Cinnamic acid derivatives
US6465471B1 (en) 1998-07-03 2002-10-15 Celltech Therapeutics Limited Cinnamic acid derivatives
US6677339B2 (en) 1998-09-28 2004-01-13 Celltech R & D Limited Phenylalanine derivatives
US6953798B1 (en) 1998-11-30 2005-10-11 Celltech R&D Limited β-alanine derivates
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
US6780874B2 (en) 2000-04-17 2004-08-24 Celltech R & D Limited Enamine derivatives
US6610700B2 (en) 2000-04-17 2003-08-26 Celltech R & D Limited Enamine derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
US6469025B1 (en) 2000-08-02 2002-10-22 Celltech R&D Ltd. 3-substituted isoquinolin-1-yl derivatives
WO2004060376A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
WO2005120477A2 (en) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
EP1904468A2 (en) * 2005-06-10 2008-04-02 Bipar Sciences, Inc. Parp modulators and treatment of cancer
EP1904468A4 (en) * 2005-06-10 2009-04-22 Bipar Sciences Inc Parp modulators and treatment of cancer
US8313729B2 (en) 2007-03-01 2012-11-20 Medibeacon, LLC Integrated photoactive small molecules and uses thereof
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
US9085606B2 (en) 2012-07-18 2015-07-21 Saint Louis University Beta amino acid derivatives as integrin antagonists
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
US10035778B2 (en) 2015-12-30 2018-07-31 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
US10577330B2 (en) 2015-12-30 2020-03-03 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
WO2021230325A1 (en) 2020-05-14 2021-11-18 宇部興産株式会社 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative
KR20230011967A (en) 2020-05-14 2023-01-25 유비이 가부시키가이샤 1,4,5,6-tetrahydropyrimidin-2-amine derivatives
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023085396A1 (en) 2021-11-12 2023-05-19 Ｕｂｅ株式会社 Pharmaceutical composition for providing treatment for or preventing alport syndrome

Also Published As

Publication number Publication date
NO20004316L (en) 2000-11-06
TR200002542T2 (en) 2001-05-21
IL137653A0 (en) 2001-10-31
EE200000506A (en) 2002-04-15
NO315703B1 (en) 2003-10-13
YU52000A (en) 2003-02-28
HUP0100865A2 (en) 2001-08-28
PL342726A1 (en) 2001-07-02
UA71906C2 (en) 2005-01-17
AP1244A (en) 2004-02-04
CA2322207A1 (en) 1999-09-10
CN1214011C (en) 2005-08-10
HUP0100865A3 (en) 2001-11-28
KR20010041584A (en) 2001-05-25
AP2000001893A0 (en) 2000-09-30
CN1291978A (en) 2001-04-18
NO20004316D0 (en) 2000-08-30
MY123908A (en) 2006-06-30
ID25591A (en) 2000-10-19
ZA994406B (en) 2000-02-11
GEP20033118B (en) 2003-11-25
EA200000804A1 (en) 2001-04-23
AU753230B2 (en) 2002-10-10
AR018139A1 (en) 2001-10-31
BR9908470A (en) 2000-12-05
EP1060164A1 (en) 2000-12-20
IS5582A (en) 2000-08-04
HRP20000574A2 (en) 2001-08-31
BG104740A (en) 2001-02-28
AU3294799A (en) 1999-09-20
OA11530A (en) 2004-05-17
NZ506598A (en) 2003-07-25
SK13002000A3 (en) 2001-07-10
JP2002505323A (en) 2002-02-19

Similar Documents

Publication Publication Date Title
AU753230B2 (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
AU765294B2 (en) Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
US6677308B1 (en) Meta-substituted phenylene sulphonamide derivatives
US5773644A (en) Cyclopropyl alkanoic acid derivatives
US6372719B1 (en) ανβ3 integrin antagonists in combination with chemotherapeutic agents
US6013651A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
US6689754B1 (en) Heterocyclic glycyl β-alanine derivatives
US6172256B1 (en) Chiral-β-amino acid compounds and derivatives thereof
US6720327B2 (en) Lactone integrin antagonists
US20040019206A1 (en) Lactone integrin antagonists
MXPA00008427A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
CZ20003218A3 (en) Derivatives of meta-azacyclic aminobenzoic acid and their derivatives that are integrin antagonists
MXPA00009967A (en) Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-520/00

Country of ref document: YU

Ref document number: 99803581.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 137653

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1200000690

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1999937927

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/248/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13002000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/008427

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2322207

Country of ref document: CA

Ref document number: 2322207

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 506598

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2000 534538

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 32947/99

Country of ref document: AU

Ref document number: 200000804

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P20000574A

Country of ref document: HR

Ref document number: 2000/02542

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PV2000-3218

Country of ref document: CZ

Ref document number: 1020007009774

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999937927

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3218

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007009774

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 32947/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007009774

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-3218

Country of ref document: CZ